Landscape → Infectious Disease

HIV

1,192 clinical trials

309 active

1192 total (since 2015)

Phase 1 Active

465 total

123

Phase 2 Active

380 total

Phase 3 Active

222 total

Phase 4 Active

243 total

Top Sponsors (Industry)

Sorted by active Active Done Failed

ViiV Healthcare 24 81 9

Gilead 22 29 3

Merck 12 28 5

TaiMed Biologics Inc. 1 5 1

United BioPharma 1 4 2

Shanxi Kangbao Biological Product Co., Ltd. 1 5 0

Johnson & Johnson 1 3 1

Henan Genuine Biotech Co., Ltd. 1 1 0

Excision BioTherapeutics 1 1 0

Jecho Biopharmaceuticals Co., Ltd. 1 0 0

BioNTech SE 1 0 0

ST Pharm Co., Ltd. 1 0 0

Immuno Cure Holding (HK) Limited 1 0 0

Jiangsu Aidea Pharmaceutical Group Co., Ltd. 1 0 0

Code Pharma 1 0 0

NCT04337450 ACTIVE NOT RECRUITING

DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old

PENTA Foundation n=386

NCT07047716 RECRUITING

Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)

Gilead Sciences n=350

NCT05994742 ACTIVE NOT RECRUITING

An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM

Queen Mary University of London n=674

NCT07044297 RECRUITING

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

Merck Sharp & Dohme LLC n=4,390

NCT07266831 RECRUITING

A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

Merck Sharp & Dohme LLC n=570

NCT02369406 ACTIVE NOT RECRUITING

Early Infant HIV Treatment in Botswana

Harvard School of Public Health (HSPH) n=67

NCT04851015 RECRUITING

Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia

Todd C. Lee MD MPH FIDSA n=416

NCT02881320 ACTIVE NOT RECRUITING

Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1

Gilead Sciences n=177

NCT07071623 RECRUITING

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

Merck Sharp & Dohme LLC n=4,580

NCT07393659 NOT YET RECRUITING

A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment

ViiV Healthcare n=183

NCT04255849 ACTIVE NOT RECRUITING

Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV

Weill Medical College of Cornell University n=700

NCT05411237 NOT YET RECRUITING

Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma

AIDS Malignancy Consortium n=130

NCT06532656 RECRUITING

Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1

Gilead Sciences n=75

NCT07327879 NOT YET RECRUITING

Comparative Dose-Response of Intrathecal Dexmedetomidine for Post-Spinal Shivering

Al-Azhar University n=120

NCT06203132 RECRUITING

DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection

ANRS, Emerging Infectious Diseases n=610

NCT06666322 RECRUITING

Platform Trial For Cryptococcal Meningitis

University of Minnesota n=2,000

NCT04951986 ACTIVE NOT RECRUITING

Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis

University of Cape Town n=732

NCT06544733 ACTIVE NOT RECRUITING

Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed

Gilead Sciences n=675

NCT02951052 ACTIVE NOT RECRUITING

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

ViiV Healthcare n=618

NCT02938520 ACTIVE NOT RECRUITING

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

ViiV Healthcare n=631

NCT04776252 ACTIVE NOT RECRUITING

Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)

Merck Sharp & Dohme LLC n=2,000

NCT04925752 ACTIVE NOT RECRUITING

Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection

Gilead Sciences n=3,292

NCT06134362 RECRUITING

Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)

ViiV Healthcare n=3,508

NCT05917509 ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy

ViiV Healthcare n=171

NCT05766501 ACTIVE NOT RECRUITING

A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)

Merck Sharp & Dohme LLC n=641

NCT06694805 RECRUITING

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

ViiV Healthcare n=332

NCT04176172 RECRUITING

Optimizing Tobacco Use Treatment for PLWHA

University of Pennsylvania n=340

NCT06790342 NOT YET RECRUITING

Optimizing Treatment of Co-occurring Smoking and Unhealthy Alcohol Use Among PWH in Nairobi, Kenya

University of Chicago n=300

NCT06317051 ACTIVE NOT RECRUITING

Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)

Kirby Institute n=300

NCT05979311 ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy

ViiV Healthcare n=473

NCT05911360 ACTIVE NOT RECRUITING

A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF

ViiV Healthcare n=205

NCT06613685 ACTIVE NOT RECRUITING

Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated

Gilead Sciences n=675

NCT05631093 ACTIVE NOT RECRUITING

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)

Merck Sharp & Dohme LLC n=553

NCT05630755 ACTIVE NOT RECRUITING

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)

Merck Sharp & Dohme LLC n=514

NCT06630299 ACTIVE NOT RECRUITING

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1

Gilead Sciences n=600

NCT02842086 ACTIVE NOT RECRUITING

Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection

Gilead Sciences n=5,399

NCT06630286 ACTIVE NOT RECRUITING

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1

Gilead Sciences n=609

NCT06333808 ACTIVE NOT RECRUITING

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

Gilead Sciences n=577

NCT05705349 ACTIVE NOT RECRUITING

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

Merck Sharp & Dohme LLC n=537

NCT05502341 ACTIVE NOT RECRUITING

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

Gilead Sciences n=689

NCT03164564 ACTIVE NOT RECRUITING

Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women

National Institute of Allergy and Infectious Diseases (NIAID) n=3,224

NCT05556720 ACTIVE NOT RECRUITING

Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial

Monash University n=960

NCT04150068 ACTIVE NOT RECRUITING

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance

Gilead Sciences n=72

NCT06497465 RECRUITING

Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment

Johns Hopkins University n=150

NCT06747507 RECRUITING

Ndovu RCT: Investing the Optimal Management of Dolutegravir Resistance

University of Nairobi n=392

NCT06444620 ACTIVE NOT RECRUITING

B/F/TAF to DTG/3TC Switch Study

University of Nairobi n=240

NCT05580666 RECRUITING

Reducing Mortality in Adults With Advanced HIV Disease (REVIVE)

Population Health Research Institute n=8,000

NCT03635788 ACTIVE NOT RECRUITING

The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

National Institute of Allergy and Infectious Diseases (NIAID) n=456

NCT07075146 RECRUITING

DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity

José Antonio Mata Marín n=306

NCT02362503 ACTIVE NOT RECRUITING

Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

ViiV Healthcare n=371

NCT03299049 ACTIVE NOT RECRUITING

Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

ViiV Healthcare n=1,049

NCT04994509 ACTIVE NOT RECRUITING

Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection

Gilead Sciences n=5,368

NCT05413122 RECRUITING

Evaluating Smoking Cessation Interventions for PWH in South Africa

Johns Hopkins University n=660

NCT05813964 RECRUITING

Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France.

ANRS, Emerging Infectious Diseases n=524

NCT05786547 RECRUITING

V+PSF-M for Tobacco Cessation in HIV Care in India

University of Colorado, Denver n=400

NCT05378399 RECRUITING

SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder

Brigham and Women's Hospital n=40

NCT05924438 ACTIVE NOT RECRUITING

A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy

Professor Francois Venter n=600

NCT03785106 ACTIVE NOT RECRUITING

Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals

The HIV Netherlands Australia Thailand Research Collaboration n=2,500

NCT04958122 RECRUITING

Cefixime Clinical Trial

University of Southern California n=400

NCT06550804 RECRUITING

Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention

University of Illinois at Chicago n=126

NCT05515770 RECRUITING

The Implementation of Pre-exposure Prophylaxis of Injectable Cabotegravir

Evandro Chagas National Institute of Infectious Disease n=1,200

NCT05546242 ACTIVE NOT RECRUITING

Improving HIV-1 Control in Africa with Long Acting Antiretrovirals

MRC/UVRI and LSHTM Uganda Research Unit n=540

NCT06587542 NOT YET RECRUITING

Effectivity of Protein Purified Derivative Treatment for Anogenital Warts in HIV Patient

Universitas Padjadjaran n=30

NCT06507059 RECRUITING

Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting Antiretrovirals

Chang Gung Memorial Hospital n=40

NCT06138600 ACTIVE NOT RECRUITING

Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa

University of Witwatersrand, South Africa n=200

NCT05154747 ACTIVE NOT RECRUITING

Long-Acting Treatment in Adolescents (LATA)

University College, London n=476

NCT06250504 RECRUITING

Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCT

Africa Health Research Institute n=2,000

NCT06133686 NOT YET RECRUITING

Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan Africa

MRC/UVRI and LSHTM Uganda Research Unit n=400

NCT04892654 RECRUITING

Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch

Chelsea and Westminster NHS Foundation Trust n=150

NCT05575518 RECRUITING

A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis

Stellah Mpagama n=414

NCT04406727 NOT YET RECRUITING

UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection

United BioPharma n=50

NCT05085171 RECRUITING

An Enhanced Package of Care to Reduce Reduce Mortality in Advanced HIV Disease

Makerere University n=2,400

NCT02859961 COMPLETED

Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection

CytoDyn, Inc. n=562

NCT04223778 COMPLETED

Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)

Merck Sharp & Dohme LLC n=672

NCT03016533 COMPLETED

Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019

ViiV Healthcare n=100

NCT04644029 TERMINATED

Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)

Merck Sharp & Dohme LLC n=730

NCT04233879 COMPLETED

Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)

Merck Sharp & Dohme LLC n=599

NCT03284866 COMPLETED

HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV

AIDS Malignancy Consortium n=536

NCT03207945 COMPLETED

Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)

University of California, San Francisco n=118

NCT04738812 COMPLETED

Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression

ANRS, Emerging Infectious Diseases n=1,330

NCT03696160 COMPLETED

The Late Presenter Treatment Optimisation Study

NEAT ID Foundation n=447

NCT04742491 COMPLETED

Pre-Exposure Prophylaxis for Transgender Women in the US and South America

HIV Prevention Trials Network n=304

NCT03682848 COMPLETED

Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents

ViiV Healthcare n=32

NCT05168813 COMPLETED

Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern

COVID-19 Prevention Network n=14,237

NCT02990858 TERMINATED

An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label Study

CytoDyn, Inc. n=43

NCT05271370 TERMINATED

An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study

CytoDyn, Inc. n=56

NCT05140954 COMPLETED

The Women TAF-FTC Benchmark Study

University of Washington n=54

NCT03913195 COMPLETED

Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular Injection

TaiMed Biologics Inc. n=43

NCT02720094 COMPLETED

Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

National Institute of Allergy and Infectious Diseases (NIAID) n=4,570

NCT03915366 COMPLETED

Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia

Hospital Universitario 12 de Octubre n=563

NCT03512418 COMPLETED

Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps)

Brigham and Women's Hospital n=30

NCT03902522 COMPLETED

PRO 140 in Treatment-Experienced HIV-1 Subjects

CytoDyn, Inc. n=6

NCT02344290 COMPLETED

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

National Institute of Allergy and Infectious Diseases (NIAID) n=7,769

NCT02245022 COMPLETED

Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study

University of Liverpool n=60

NCT03965923 COMPLETED

Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in Pregnancy

National Institute of Allergy and Infectious Diseases (NIAID) n=1,104

NCT02259127 COMPLETED

ODYSSEY (PENTA 20)

PENTA Foundation n=792

NCT02059499 COMPLETED

Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions

AIDS Malignancy Consortium n=91

NCT04193189 COMPLETED

B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B

National Institute of Allergy and Infectious Diseases (NIAID) n=638

NCT03311945 COMPLETED

Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM

Judit Pich n=33

NCT07043049 COMPLETED

Comparison of Prophylactic Use of Tramadol Versus Ketamine for Prevention of Post Spinal Anesthesia Shivering

Syed Muhammad Abbas n=92

NCT02285114 COMPLETED

Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen

Gilead Sciences n=41

NCT03029689 COMPLETED

Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDY

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia n=61

NCT05601128 COMPLETED

A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) n=12

NCT03333083 TERMINATED

Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen

Judit Pich n=17

NCT03231358 COMPLETED

Our Family Our Future: A Resilience-oriented Family Intervention to Prevent Adolescent HIV/STI Infection and Depression in South Africa

Brown University n=1,758

NCT04223791 COMPLETED

Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)

Merck Sharp & Dohme LLC n=643

NCT03547908 COMPLETED

Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults

Gilead Sciences n=244

NCT04034862 COMPLETED

Impact of DOlutegravir+Lamivudine Simplification on HIV-1 Reservoirs

University of Liege n=36

NCT02460900 COMPLETED

Optimizing Smoking Cessation for People With HIV/AIDS Who Smoke

University of Maryland, Baltimore n=184

NCT03249181 COMPLETED

Dolutegravir in Pregnant HIV Mothers and Their Neonates

University of Liverpool n=268

NCT03342027 COMPLETED

Smoking Cessation Interventions for People Living With HIV in Nairobi, Kenya

University of Maryland, Baltimore n=300

NCT03227861 COMPLETED

A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care

Janssen Scientific Affairs, LLC n=109

NCT04652700 TERMINATED

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)

Merck Sharp & Dohme LLC n=494

NCT04233216 COMPLETED

Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)

Merck Sharp & Dohme LLC n=35

NCT02987530 COMPLETED

National Multicenter Trial Evaluating Two Treatments in Patients with Primary Human Immunodeficiency Virus (HIV-1) Infection

ANRS, Emerging Infectious Diseases n=101

NCT05349838 COMPLETED

Open-Label Multi-Centre Randomised Switch Study to Evaluate Virological Efficacy Over 96Weeks Of 2-Drug Therapy With Dolutegravir(DTG)/Rilpivirine(RPV) Fixed Dose Combination(FDC) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTI Mutation K103N

NEAT ID Foundation n=140

NCT05896748 COMPLETED

Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study

ViiV Healthcare n=94

NCT02403674 COMPLETED

Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)

Merck Sharp & Dohme LLC n=734

NCT02397096 COMPLETED

Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)

Merck Sharp & Dohme LLC n=673

NCT03070223 COMPLETED

PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332)

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections n=602

NCT03563742 TERMINATED

A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Janssen Research & Development, LLC n=58

NCT01854762 TERMINATED

Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection

Fundação Bahiana de Infectologia n=33

NCT03671109 COMPLETED

Improving Maternal heAlth by Reducing Malaria in African HIV Women

Barcelona Institute for Global Health n=666

NCT05592613 COMPLETED

Next Generation Ingestible Sensors for Medication Adherence Measurement

Brigham and Women's Hospital n=15

NCT04937881 COMPLETED

PK of TAF and TDF for PrEP in Pregnant and Postpartum Women

University of California, Los Angeles n=39

NCT02429791 COMPLETED

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)

ViiV Healthcare n=510

NCT02422797 COMPLETED

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)

ViiV Healthcare n=518

NCT02968849 COMPLETED

Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa

National Institute of Allergy and Infectious Diseases (NIAID) n=5,404

NCT04121195 COMPLETED

Dose Escalation Study to Determine the Pharmacokinetics of Atazanavir Administered With RIfampicin to HIV Positive Adults on sEcond-line ART Regimen With Suppressed HIV-1 Viral Load

University of Liverpool n=26

NCT04542070 COMPLETED

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed

ViiV Healthcare n=687

NCT06403787 COMPLETED

Effect of Aerobic Training and Ginkgo Biloba on Lipids Levels in HIV-positive Patients Undergoing Antiretroviral Treatment

University of Guadalajara n=28

NCT04399551 COMPLETED

A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries

ViiV Healthcare n=437

NCT03092817 COMPLETED

Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial)

Oxford University Clinical Research Unit, Vietnam n=520

NCT03727152 COMPLETED

Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir

The HIV Netherlands Australia Thailand Research Collaboration n=170

NCT03493568 TERMINATED

Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to E/C/F/TAF in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE)

IRCCS San Raffaele n=100

NCT04653194 COMPLETED

Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'

Chelsea and Westminster NHS Foundation Trust n=36

NCT01837277 COMPLETED

Impact of a Dolutegravir-based Regimen on Early Mortality of AIDS Patients

Fundação Bahiana de Infectologia n=186

NCT02831764 COMPLETED

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

ViiV Healthcare n=722

NCT02486133 COMPLETED

Dual Therapy With Boosted Darunavir + Dolutegravir

Technical University of Munich n=269

NCT04021290 COMPLETED

Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)

ViiV Healthcare n=493

NCT04808973 COMPLETED

DTG Plus 3TC for Prophylaxis of Mother-to-child Transmission of HIV Infection in Pregnant Women

Fundação Bahiana de Infectologia n=20

NCT04416906 COMPLETED

A Test and Treat Strategy in New HIV Diagnosis.

Judit Pich Martínez n=100

NCT05896761 COMPLETED

A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants

ViiV Healthcare n=118

NCT02831673 COMPLETED

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

ViiV Healthcare n=719

NCT04140266 COMPLETED

Safety and Drug Detection Study of Dapivirine Vaginal Ring and Oral TRUVADA® in Breastfeeding Mother-Infant Pairs

National Institute of Allergy and Infectious Diseases (NIAID) n=394

NCT04433780 COMPLETED

DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV

Professor Francois Venter n=133

NCT03446573 COMPLETED

Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)

ViiV Healthcare n=743

NCT05457530 WITHDRAWN

Doravirine and Weight Gain in Antiretroviral Naive

Prism Health North Texas

NCT03149211 WITHDRAWN

To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults

United BioPharma

NCT04001803 COMPLETED

Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)

ViiV Healthcare n=115

NCT03656783 COMPLETED

Effects of Biktarvy on CFR in Stable HIV Patients

Brigham and Women's Hospital n=25

NCT03122262 COMPLETED

ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy

Professor Francois Venter n=1,110

NCT03870438 COMPLETED

Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention

ANRS, Emerging Infectious Diseases n=1,506

NCT03048422 COMPLETED

Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants

National Institute of Allergy and Infectious Diseases (NIAID) n=643

NCT02660905 COMPLETED

HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection

Ottawa Hospital Research Institute n=25

NCT03227731 COMPLETED

Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women

University of KwaZulu n=540

NCT02483078 COMPLETED

Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140

CytoDyn, Inc. n=52

NCT02858037 COMPLETED

Trial to Assess the Continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women

International Partnership for Microbicides, Inc. n=1,456

NCT02862171 COMPLETED

To Assess Continued Safety of and Adherence to the Dapivirine (25 mg) Vaginal Ring-004 in Healthy, HIV-negative Women

International Partnership for Microbicides, Inc. n=941

NCT02434848 COMPLETED

A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses

Sheffield Teaching Hospitals NHS Foundation Trust n=13

NCT04079452 COMPLETED

Doravirine Concentrations and Antiviral Activity in Cerebrospinal Fluid in HIV-1 Infected Individuals

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia n=15

NCT03275350 COMPLETED

Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up

Oregon Health and Science University n=114

NCT05306704 COMPLETED

High-Dose Vitamin D3 Supplementation in the Treatment of Human Immune Deficiency Virus Patients Trial

University of the Punjab n=95

NCT03403569 COMPLETED

Safety and Efficacy of Triptolide Wilfordii in New Onset HIV-1 Infection

Peking Union Medical College Hospital n=353

NCT02817451 COMPLETED

DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants

Sanofi Pasteur, a Sanofi Company n=53

NCT02607956 COMPLETED

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Gilead Sciences n=657

NCT02607930 COMPLETED

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Gilead Sciences n=631

NCT03110380 COMPLETED

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed

Gilead Sciences n=567

NCT02269917 COMPLETED

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

Janssen R&D Ireland n=1,149

NCT03129113 COMPLETED

Adding MAraViroc &/or METformin for Hepatic Steatosis in People Living With HIV

University College, London n=90

NCT03945981 COMPLETED

Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults

ViiV Healthcare n=131

NCT02776748 COMPLETED

PrEP in Breastfeeding Study

University of Washington n=50

NCT03631732 COMPLETED

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

Gilead Sciences n=496

NCT02777229 COMPLETED

Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings

ANRS, Emerging Infectious Diseases n=616

NCT03297216 COMPLETED

Improving Pregnancy Outcomes With Progesterone

University of North Carolina, Chapel Hill n=800

NCT02738138 COMPLETED

A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)

AbbVie n=153

NCT02499978 WITHDRAWN

Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity

Stanford University

NCT04695613 COMPLETED

Shivering Control After Percutaneous Nephrolithotomy

Assiut University n=80

NCT02383108 COMPLETED

Strategy for Maintenance of HIV Suppression With Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children

PENTA Foundation n=318

NCT02707861 COMPLETED

Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1

TaiMed Biologics Inc. n=79

NCT02870790 COMPLETED

Expanded PrEP Implementation in Communities in NSW

Kirby Institute n=9,733

NCT02178592 COMPLETED

Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection

ViiV Healthcare n=113

NCT02603107 COMPLETED

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

Gilead Sciences n=578

NCT02797587 COMPLETED

Studying Partial-agonists for Ethanol and Tobacco Elimination in Russians With HIV (St PETER HIV)

Boston Medical Center n=400

NCT03525210 COMPLETED

Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients

Universitaire Ziekenhuizen KU Leuven n=271

NCT03405935 COMPLETED

Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years

Gilead Sciences n=86

NCT02603120 COMPLETED

Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed

Gilead Sciences n=567

NCT03708861 WITHDRAWN

Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients

University of Turin, Italy

NCT02600819 COMPLETED

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis

Gilead Sciences n=55

NCT02478632 COMPLETED

Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen

ViiV Healthcare n=102

NCT03327155 COMPLETED

Western Australian Pre-exposure Prophylaxis for HIV Implementation Trial

Kirby Institute n=900

NCT04360759 WITHDRAWN

Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19

University of Cape Town

NCT03517358 COMPLETED

Virological Suppression in HIV Positive Patients Involved in a Novel Standardized Adherence Protocol

University of California, Davis n=10

NCT02616029 COMPLETED

Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

Gilead Sciences n=66

NCT02305927 COMPLETED

Trial of Vitamin D in HIV Progression, Birth Outcomes, and Child Health

Wafaie Fawzi n=2,300

NCT02475629 COMPLETED

Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV

TaiMed Biologics Inc. n=40

NCT02616783 COMPLETED

Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years

Gilead Sciences n=167

NCT02652624 COMPLETED

Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

Gilead Sciences n=472

NCT02358226 COMPLETED

HIV & Drug Abuse Prevention for South African Men

University of California, Los Angeles n=1,211

NCT03595709 COMPLETED

Therapeutic Drug Monitoring Study of Reduced-Dose Efavirenz (400 mg) in Combo Tablet for Patients Receiving Atripla With Viral Suppression in Taiwan

Yu-Jay Corp. n=50

NCT02345252 COMPLETED

Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

Gilead Sciences n=632

NCT02345226 COMPLETED

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

Gilead Sciences n=881

NCT02976259 COMPLETED

Kinetics of HIV-RNA Decay in Seminal Plasma of Men Treated by Dolutegravir at the Time of Primary HIV Infection

Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba n=20

NCT02980016 COMPLETED

Evaluation of the Effect of 3HP vs Periodic 3HP vs 6H in HIV-Positive Individuals

The Aurum Institute NPC n=4,027

NCT02469246 COMPLETED

Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC

Gilead Sciences n=567

NCT02426112 COMPLETED

Bronchopulmonary Function in Response to Azithromycin Treatment for Chronic Lung Disease in HIV-infected Children

London School of Hygiene and Tropical Medicine n=347

NCT02426840 COMPLETED

Calcium and High-dose Vitamin D Supplementation on Bone Mineral Density Among HIV-infected Children and Adolescents

Chiang Mai University n=200

NCT02150993 COMPLETED

First-Line Treatment for HIV-2

ANRS, Emerging Infectious Diseases n=210

NCT02600325 COMPLETED

Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV

Erasmus Medical Center n=80

NCT02346487 COMPLETED

Prospective Study of Lopinavir Based ART for HIV Infected childreN Globally (LIVING Study)

Drugs for Neglected Diseases n=1,003

NCT03369327 COMPLETED

Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus

Tehran University of Medical Sciences n=232

NCT02692027 COMPLETED

Same-day ART Initiation Versus Standard of Care After Positive HIV-test Result in Rural Lesotho

Swiss Tropical & Public Health Institute n=276

NCT02998320 COMPLETED

Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis

Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux n=101

NCT02003703 COMPLETED

Comparative Efficacy of an Intensified Re-vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected With HIV .

Universidad de Valparaiso n=107

NCT02273765 COMPLETED

Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis

ANRS, Emerging Infectious Diseases n=460

NCT02707601 COMPLETED

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment

Gilead Sciences n=150

NCT02605954 COMPLETED

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

Gilead Sciences n=275

NCT02596334 TERMINATED

Study to Evaluate the Efficacy of MONotherapy of TiviCAY® Versus a Triple Therapy in HIV-1-infected Patients

Centre Hospitalier Régional d'Orléans n=158

NCT02785666 COMPLETED

Swiss HCVree Trial

University of Zurich n=150

NCT02671383 COMPLETED

Evaluation of Low-dose Darunavir in a Switch Study

Willem Daniel Francois Venter n=300

NCT02369627 COMPLETED

Facilitating HIV Testing Among Young Adult MSM Through Social Networking

Rhode Island Hospital n=425

NCT03008850 COMPLETED

Shivering Prevention During Cesarean Section by Intrathecal Injection of Magnesium Sulfate

Assiut University n=84

NCT04929028 RECRUITING

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

NCT06101342 ACTIVE NOT RECRUITING

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)

Gilead Sciences

NCT07028385 ACTIVE NOT RECRUITING

Safety and Impact of Baricitinib on Cell Surivival Pathways, HIV-1 Reservoir and Inflamation in People With HIV-1

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

NCT04019197 ACTIVE NOT RECRUITING

Effects of Semaglutide in HIV-Associated Lipohypertrophy

Case Western Reserve University

NCT05470491 RECRUITING

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

National Cancer Institute (NCI)

NCT07433387 RECRUITING

Exploratory Study of LP-98 for Injection in ART-Naive HIV-Infected Individuals

Shanxi Kangbao Biological Product Co., Ltd.

NCT07144293 RECRUITING

Improving Physical Ability and Cellular Senescence Elimination in HIV

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04357821 ACTIVE NOT RECRUITING

Combinatorial Therapy to Induce an HIV Remission

University of California, San Francisco

NCT04375800 RECRUITING

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

Merck Sharp & Dohme LLC

NCT07209267 NOT YET RECRUITING

Baricitinib Curative Repression of HIV-1

Emory University

NCT05556746 ACTIVE NOT RECRUITING

Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB

Brigham and Women's Hospital

NCT07215468 RECRUITING

HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study

TaiMed Biologics Inc.

NCT04353778 RECRUITING

Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV

Icahn School of Medicine at Mount Sinai

NCT07288190 NOT YET RECRUITING

Phase 2b, Open Label, Multisite, Randomized Crossover Study of DPP Versus 2PR

HIV Prevention Trials Network

NCT06480578 RECRUITING

An Integrated Intervention Using a Pill Ingestible Sensor System

University of California, Los Angeles

NCT02494986 ACTIVE NOT RECRUITING

A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies

Janssen Sciences Ireland UC

NCT06071767 RECRUITING

Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05869643 RECRUITING

A Clinical Trial of STP0404 in Adults With HIV-1 Infection

ST Pharm Co., Ltd.

NCT05419024 RECRUITING

Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption

National Cancer Institute (NCI)

NCT05052996 ACTIVE NOT RECRUITING

Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV

Gilead Sciences

NCT07384624 NOT YET RECRUITING

Combining Latency Reversing Agents to Address the HIV Reservoir

Erasmus Medical Center

NCT06411223 ACTIVE NOT RECRUITING

Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs

Yale University

NCT07143968 NOT YET RECRUITING

A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV

Naga P. Chalasani

NCT05382208 ACTIVE NOT RECRUITING

Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)

Weill Medical College of Cornell University

NCT07145164 ENROLLING BY INVITATION

Interleukin-15 to Promote Post-ART Control of HIV

Michael Peluso, MD

NCT07054931 RECRUITING

Combination Vaccination and Broadly Neutralising Antibody Therapy in HIV

University of Oxford

NCT07221214 NOT YET RECRUITING

GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV

Vanderbilt University Medical Center

NCT06705478 NOT YET RECRUITING

Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

National Institute of Allergy and Infectious Diseases (NIAID)

NCT07007221 NOT YET RECRUITING

Clinical Trials to Evaluate Metformin to Treat Depression in People Living With HIV

University of Minnesota

NCT07336797 RECRUITING

Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy

Abdelrahman Mahmoud

NCT06004830 RECRUITING

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 1

Yale University

NCT07040592 RECRUITING

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide

Yale University

NCT04983030 ACTIVE NOT RECRUITING

Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults

Boris Juelg, MD PhD

NCT05996471 ACTIVE NOT RECRUITING

A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

ViiV Healthcare

NCT07308782 RECRUITING

A Phase Ⅱa Clinical Study of CL-197 Capsules

Henan Genuine Biotech Co., Ltd.

NCT04141449 ACTIVE NOT RECRUITING

A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation

Brigham and Women's Hospital

NCT05551273 ACTIVE NOT RECRUITING

Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV

National Institute of Allergy and Infectious Diseases (NIAID)

NCT06812494 RECRUITING

A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05187429 RECRUITING

Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy

University of Melbourne

NCT07202546 NOT YET RECRUITING

A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

ViiV Healthcare

NCT05488431 RECRUITING

Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)

Priscilla Hsue, MD

NCT06519994 ACTIVE NOT RECRUITING

Feasibility of Intravaginal Artesunate as Adjuvant HPV & Cervical Precancer Treatment in Kenya

UNC Lineberger Comprehensive Cancer Center

NCT05590455 RECRUITING

Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis

ANRS, Emerging Infectious Diseases

NCT05122767 ACTIVE NOT RECRUITING

Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS)

The Aurum Institute NPC

NCT05122026 ACTIVE NOT RECRUITING

Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV

The Aurum Institute NPC

NCT07275606 NOT YET RECRUITING

A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1

ViiV Healthcare

NCT06749054 RECRUITING

Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children

Gilead Sciences

NCT06935838 RECRUITING

Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV

University of Hawaii

NCT07030920 RECRUITING

Reducing Systemic Inflammation in People on Antiretroviral Therapy

Centre hospitalier de l'Université de Montréal (CHUM)

NCT05719441 RECRUITING

A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02479698 RECRUITING

Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

M.D. Anderson Cancer Center

NCT06741397 ACTIVE NOT RECRUITING

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)

ViiV Healthcare

NCT05443555 RECRUITING

Gabapentin to Reduce Alcohol and Improve Viral Load Suppression

Boston Medical Center

NCT06891066 ACTIVE NOT RECRUITING

A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)

Merck Sharp & Dohme LLC

NCT04800159 ACTIVE NOT RECRUITING

Cannabis Effects on Antiretroviral Therapy Pharmacokinetics and Neurotoxicity

University of California, San Diego

NCT07216794 NOT YET RECRUITING

Small Trial of Alendronate Impact on the Reservoir of HIV

National Institute of Allergy and Infectious Diseases (NIAID)

NCT06843902 RECRUITING

Improving Coronary Vascular Health in Women

Massachusetts General Hospital

NCT07090174 NOT YET RECRUITING

Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV

Weill Medical College of Cornell University

NCT02140255 RECRUITING

Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

National Institute of Allergy and Infectious Diseases (NIAID)

NCT06101329 ACTIVE NOT RECRUITING

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)

Gilead Sciences

NCT05570812 RECRUITING

Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV

Massachusetts General Hospital

NCT05586581 RECRUITING

SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy

Yale University

NCT04648280 RECRUITING

Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class Antiretroviral Resistance

PENTA Foundation

NCT06513312 ACTIVE NOT RECRUITING

Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)

Gilead Sciences

NCT06599658 RECRUITING

COVID-19 Booster and IIV Schedule in Immunocompromised Hosts

McGill University Health Centre/Research Institute of the McGill University Health Centre

NCT06691243 RECRUITING

Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV

University of Maryland, Baltimore

NCT04521803 RECRUITING

High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis

University of Cape Town

NCT06805656 NOT YET RECRUITING

Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Antiretrovirals

Federal University of São Paulo

NCT06799650 RECRUITING

Clinical Trial of Gammora® Plus Antiretroviral Treatment for HIV

Federal University of São Paulo

NCT05123144 ACTIVE NOT RECRUITING

A Hybrid Type II Trial of the Optimizing Resilience and Coping With HIV Through Internet Delivery in Ryan White Clinics in Chicago

Northwestern University

NCT06554717 RECRUITING

Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV

Massachusetts General Hospital

NCT06034938 RECRUITING

DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road)

University Hospital, Caen

NCT07081763 NOT YET RECRUITING

Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment Interruption

ANRS, Emerging Infectious Diseases

NCT05729568 ACTIVE NOT RECRUITING

A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

Gilead Sciences

NCT04648046 RECRUITING

CAR-T Cells for HIV Infection

Steven Deeks

NCT06660498 RECRUITING

Pomalidomide as an Immune-enhancing Agent for the Control of HIV

University of Aarhus

NCT06640192 RECRUITING

Administration of High Doses of Antiretroviral Drugs to Eliminate the Latent HIV-1 Reservoir

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

NCT05288790 RECRUITING

Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT

Vanderbilt University Medical Center

NCT06006143 RECRUITING

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2

Yale University

NCT06774872 RECRUITING

Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Successfully

Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida

NCT06508749 RECRUITING

The Tatelo Plus Study

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05660980 RECRUITING

Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05849038 RECRUITING

Inflammation and Depression in People With HIV

Emory University

NCT06624839 RECRUITING

Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV

University of Maryland, Baltimore

NCT05527418 RECRUITING

Safety, Tolerance and Antiretroviral Activity of Dasatinib: a Pilot Clinical Trial in Patients With Recent HIV-1 Infection

Eva Bonfill

NCT02797470 ACTIVE NOT RECRUITING

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

AIDS Malignancy Consortium

NCT04505501 ACTIVE NOT RECRUITING

Reducing HIV Persistence in Lymph Nodes by Interleukin-15 (IL-15) Receptor Super-agonist (N-803) in Acute HIV Infection

Thai Red Cross AIDS Research Centre

NCT02437851 ACTIVE NOT RECRUITING

Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection

AIDS Malignancy Consortium

NCT05668026 RECRUITING

Administration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ART

University of Aarhus

NCT05452564 RECRUITING

Baricitinib for Reduction of HIV - CNS

William Tyor

NCT05514899 RECRUITING

Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV

University of California, San Diego

NCT06338826 NOT YET RECRUITING

Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses

ANRS, Emerging Infectious Diseases

NCT06205602 RECRUITING

Antiretrovirals Combined With Antibodies for HIV-1 Cure In Africa

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NCT06791928 ENROLLING BY INVITATION

Peer Delivered HIV/Syphilis Self-Testing With Assisted Partner Notification Services

Makerere University

NCT04513626 RECRUITING

HIV-1 Infected Patients, Phase II Trial, Dual Combination Doravirine/Raltegravir Open Label

Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida

NCT05300035 RECRUITING

Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control

ANRS, Emerging Infectious Diseases

NCT06719310 RECRUITING

Phase Ib/IIa Clinical Study of ACC017 Tablets

Jiangsu Aidea Pharmaceutical Group Co., Ltd.

NCT05947890 RECRUITING

Evaluating the Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living With and Without HIV in South Africa

HIV Vaccine Trials Network

NCT06676410 RECRUITING

Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants

Code Pharma

NCT06672653 NOT YET RECRUITING

Tolerance and Effectiveness of C14 on HPV Infection

MGB Pharma

NCT03684655 RECRUITING

Imaging Immune Activation in HIV by PET-MR

CellSight Technologies, Inc.

NCT06631365 RECRUITING

PrEPsmart 2-1-1 Pilot

Public Health Foundation Enterprises, Inc.

NCT06626555 NOT YET RECRUITING

Clinical Trial to Evaluate the Effects of Letermovir Prophylaxis on T-cell Immune Activation in Participants With Treated HIV-1 Infection

University College, London

NCT03731559 RECRUITING

Efficacy, Safety and Pharmacokinetics of DTG with RIF

The HIV Netherlands Australia Thailand Research Collaboration

NCT05674656 RECRUITING

Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics

ViiV Healthcare

NCT05057858 ACTIVE NOT RECRUITING

The Women TDF-FTC Benchmark Study

University of Washington

NCT04480554 RECRUITING

Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1

University of Pennsylvania

NCT04319367 RECRUITING

A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs).

Imperial College London

NCT04568460 ACTIVE NOT RECRUITING

Standing Tall (Yima Nkqo)

Brigham and Women's Hospital

NCT04985890 NOT YET RECRUITING

A Proof of Concept Study to Evaluate the Effect of UB-421 in Combination With Chidamide on HIV Viral Reservoir

UBP Greater China (Shanghai) Co., Ltd

NCT05597800 NOT YET RECRUITING

Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome

Universita di Verona

NCT05993767 COMPLETED

UNIVERSAL 1: Pharmacokinetic Study of a Novel DTG/FTC/TAF Dose Ratio for Children

PENTA Foundation

NCT05991622 WITHDRAWN

Combined Injectable Treatment for HIV and OUD

Rhode Island Hospital

NCT06435026 COMPLETED

Optimizing PrEP Regimens for Pregnant Women in Sub-Saharan Africa (O-PrEP Study) - Stage 1

University of North Carolina, Chapel Hill

NCT06061536 COMPLETED

Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients.

Shanxi Kangbao Biological Product Co., Ltd.

NCT06560489 COMPLETED

Pharmacokinetics and Efficacy of Multiple Dosing of LP-98 for Injection in HIV-infected Patients

Shanxi Kangbao Biological Product Co., Ltd.

NCT03601806 COMPLETED

Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection

AIDS Malignancy Consortium

NCT03497676 COMPLETED

More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04153136 COMPLETED

The ENCHANTMENT HIV Study

Massachusetts General Hospital

NCT04564547 COMPLETED

Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]

Merck Sharp & Dohme LLC

NCT05832281 TERMINATED

Role of CBD in Improving Alexithymia

University of California, San Diego

NCT05281510 COMPLETED

Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women

Gilead Sciences

NCT06657885 WITHDRAWN

CAbotégravir LENacapavir DUal Long Acting

Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba

NCT04930744 COMPLETED

Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)

University of Massachusetts, Worcester

NCT06045507 COMPLETED

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

Merck Sharp & Dohme LLC

NCT06029712 COMPLETED

Heart Failure Polypill at a Safety Net Hospital

University of California, San Francisco

NCT03593187 COMPLETED

A Study Evaluating the Safety of Cal-1 (LVsh5/C46) Drug Product in HIV-1 Infected Patient With High Risk Lymphoma

Assistance Publique - Hôpitaux de Paris

NCT05099965 COMPLETED

Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)

National Institute of Allergy and Infectious Diseases (NIAID)

NCT06032546 TERMINATED

A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

AbbVie

NCT05275998 COMPLETED

TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals

TaiMed Biologics Inc.

NCT06061081 TERMINATED

A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1

ViiV Healthcare

NCT03633721 COMPLETED

Acute Effects of Cannabis on Cognition and Mobility in Older HIV-infected and HIV-Un-infected Women

Albert Einstein College of Medicine

NCT05936567 COMPLETED

Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria

Incyte Corporation

NCT05571319 COMPLETED

A Pilot Study of Metformin to Reduce Cerebrovascular Dysfunction in Participants With HIV and Metabolic Syndrome.

University of Stellenbosch

NCT04734652 COMPLETED

INSTI's For The Management of HIV-associated TB

Centre for the AIDS Programme of Research in South Africa

NCT06039579 COMPLETED

Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults

ViiV Healthcare

NCT03091374 COMPLETED

Impact of Recombinant Human Growth Hormone on HIV Persistence

McGill University Health Centre/Research Institute of the McGill University Health Centre

NCT05780073 COMPLETED

Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment

Fundació Institut Germans Trias i Pujol

NCT06005610 COMPLETED

Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03619278 WITHDRAWN

Evaluating a Combination of Immune-based Therapies to Achieve a Remission of HIV Infection

Judit Pich

NCT02906007 COMPLETED

Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV

National Institute of Allergy and Infectious Diseases (NIAID)

NCT06022406 COMPLETED

Fecal Microbiota Translantation (FMT) to Reduce Inflammation in PLWH: The Gutsy Pilot Study

Jean-Pierre Routy

NCT06139796 WITHDRAWN

Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV

PENTA Foundation

NCT02859558 COMPLETED

Early ART to Limit Infection and Establishment of Reservoir

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NCT04311502 TERMINATED

Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05539989 WITHDRAWN

Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa

International Maternal Pediatric Adolescent AIDS Clinical Trials Group

NCT06336434 WITHDRAWN

CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04003103 COMPLETED

Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)

Merck Sharp & Dohme LLC

NCT04556981 COMPLETED

Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV

Gates Medical Research Institute

NCT05630885 COMPLETED

A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03603808 COMPLETED

VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions

AIDS Malignancy Consortium

NCT05582694 WITHDRAWN

A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection

National Institute of Allergy and Infectious Diseases (NIAID)

NCT06214052 COMPLETED

VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1

ViiV Healthcare

NCT03201939 TERMINATED

Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria

Vanderbilt University Medical Center

NCT03141060 COMPLETED

Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03739996 COMPLETED

Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04692077 COMPLETED

Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03707977 COMPLETED

Dual bNAb Treatment in Children

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04173819 COMPLETED

Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults

International AIDS Vaccine Initiative

NCT03568812 COMPLETED

The Role of Probiotics in HIV Patients With Immunological Non-Responder

Indonesia University

NCT02330419 COMPLETED

Better Than Study: Targeting Heavy Alcohol Use With Naltrexone Among Men Who Have Sex With Men (MSM)

University of California, San Francisco

NCT03041012 COMPLETED

Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART

Aarhus University Hospital

NCT04880785 COMPLETED

Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine

Fundacion SEIMC-GESIDA

NCT04840199 TERMINATED

A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03386578 COMPLETED

Evaluating the Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for HIV Prevention During Pregnancy and Postpartum

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02652260 COMPLETED

Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)

Merck Sharp & Dohme LLC

NCT02919306 COMPLETED

Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults

Janssen Vaccines & Prevention B.V.

NCT04012931 COMPLETED

A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed

Janssen Research & Development, LLC

NCT04066881 COMPLETED

A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP

MRC/UVRI and LSHTM Uganda Research Unit

NCT04286282 COMPLETED

Neuroinflammation and Modulating Factors in Depression and HIV

University of Minnesota

NCT04083170 TERMINATED

Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers

Fred Hutchinson Cancer Center

NCT04824131 COMPLETED

Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females

National Institute of Allergy and Infectious Diseases (NIAID)

NCT06711913 COMPLETED

Role of Intravenous Dexmedetomidine in Reducing Shivering After Shivering Cesarean Section Due to Spinal Anesthesia

Liaquat National Hospital & Medical College

NCT05330143 COMPLETED

Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV

Ascletis Pharmaceuticals Co., Ltd.

NCT03384784 COMPLETED

Effect of Galantamine on Inflammation and Cognition

University of Pennsylvania

NCT04871113 COMPLETED

A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults

ViiV Healthcare

NCT02722421 COMPLETED

Pharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected Women

University of Nebraska

NCT04143594 COMPLETED

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV

Gilead Sciences

NCT03991013 COMPLETED

Tenofovir-lamivudine-dolutegravir Combination as Second-line ART: a Randomised Controlled Trial

University of Cape Town

NCT04216589 COMPLETED

Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03284710 COMPLETED

Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02735863 COMPLETED

ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment

Abivax S.A.

NCT04272242 TERMINATED

Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03282799 COMPLETED

Pharmacologic Strategies for the Etonogestrel Implant in HIV-Infected Women

Catherine Anne Chappell

NCT05022212 COMPLETED

Phase 2 Trial of LACTIN-V in Women at High Risk of HIV Acquisition

University of California, San Francisco

NCT02741128 COMPLETED

Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults

Sanofi Pasteur, a Sanofi Company

NCT03851588 COMPLETED

Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis

University of Cape Town

NCT04042740 COMPLETED

Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NCT03382834 COMPLETED

Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04493216 TERMINATED

A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults

ViiV Healthcare

NCT03094286 COMPLETED

Durvalumab in HIV-1 Patients With Solid Tumors

Spanish Lung Cancer Group

NCT03639311 COMPLETED

Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study

ViiV Healthcare

NCT03666871 COMPLETED

CCR5-modified CD4+ T Cells for HIV Infection

University of Cincinnati

NCT04692467 COMPLETED

Treatment of Early Hypertension Among Persons Living With HIV in Haiti

Weill Medical College of Cornell University

NCT03652623 COMPLETED

Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - PK Study

Hektoen Institute for Medical Research

NCT02471430 COMPLETED

Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy

Massachusetts General Hospital

NCT02542852 COMPLETED

A Study of a Nucleoside Sparing Regimen in HIV-1 Infected Patients With Detectable Viremia

Castagna Antonella

NCT03198559 TERMINATED

Combination Latency Reversal With High Dose Disulfiram Plus Vorinostat in HIV-infected Individuals on ART

University of Melbourne

NCT04295772 COMPLETED

Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028)

Merck Sharp & Dohme LLC

NCT04900038 TERMINATED

A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults

ViiV Healthcare

NCT03431168 COMPLETED

A Novel Regimen to Prevent Malaria and STI in Pregnant Women With HIV

University of Alabama at Birmingham

NCT05115838 WITHDRAWN

Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043)

Merck Sharp & Dohme LLC

NCT02336074 COMPLETED

Research In Viral Eradication of HIV Reservoirs

Imperial College London

NCT02741323 COMPLETED

Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04120415 COMPLETED

A HIV Vaccine Trial in Individuals Who Started Antiretrovirals During Primary or Chronic Infection (EHVA T02)

ANRS, Emerging Infectious Diseases

NCT03284541 COMPLETED

Online HIV Prevention for Young Male Couples

Northwestern University

NCT04364035 COMPLETED

Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive Patients

Aelix Therapeutics

NCT03669133 TERMINATED

Vitamin E for NASH Treatment in HIV Infected Individuals

Indiana University School of Medicine

NCT02213328 COMPLETED

Acceptability, Safety, and Use of Daily Truvada Pre-Exposure Prophylaxis in Adolescents

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03760458 COMPLETED

The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02475915 COMPLETED

Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection

SEARCH Research Foundation

NCT03593655 COMPLETED

Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02431325 COMPLETED

A Study of the Gut Barrier and Blood Vessel Inflammation in Individuals With and Without HIV

Massachusetts General Hospital

NCT03606213 COMPLETED

Therapeutic Vaccination in Treated HIV Disease

Steven Deeks

NCT03208231 COMPLETED

Evaluating the Safety and Antiviral Activity of Monoclonal Antibody VRC01 in Infants With HIV Receiving Combination Antiretroviral Therapy

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03837756 COMPLETED

Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV

University of Aarhus

NCT03304093 COMPLETED

Immunotherapy by Nivolumab for HIV+ Patients

Intergroupe Francophone de Cancerologie Thoracique

NCT02272946 COMPLETED

Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk

Priscilla Hsue, MD

NCT03060629 TERMINATED

A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa

Janssen Vaccines & Prevention B.V.

NCT05306249 COMPLETED

Effects of Cannabidiol (CBD) on the Activation of Autophagy and Inflammation Genes, Functional Consequences in Virologically Controlled HIV-infected Patients

Centre Hospitalier Régional d'Orléans

NCT04084444 COMPLETED

Safety and Efficacy of T8 on Treating Chronic Abnormal Immune Activation in HIV/AIDS Patients

Shanghai Pharmaceuticals Holding Co., Ltd

NCT02990325 COMPLETED

A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults

Abivax S.A.

NCT03272347 COMPLETED

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

Merck Sharp & Dohme LLC

NCT03122223 COMPLETED

Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05064956 COMPLETED

Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study)

London School of Hygiene and Tropical Medicine

NCT05056974 COMPLETED

A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs

United BioPharma

NCT03332095 COMPLETED

Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03960541 TERMINATED

Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003)

Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

NCT03186534 COMPLETED

Randomized Trial of an HIV Prevention and Relationship Education Program for Young Male Couples

Northwestern University

NCT03435146 COMPLETED

Safety Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine and Isoniazid or Standard Isoniazid Preventive Therapy in HIV+ Patients (DOLPHIN & DOLPHIN TOO)

The Aurum Institute NPC

NCT04334915 WITHDRAWN

Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05351684 COMPLETED

Effect of Dolutegravir Intensification on HIV-1 Reservoirs

University of Liege

NCT04052139 COMPLETED

St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Gabapentin

Boston Medical Center

NCT02660710 COMPLETED

Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma

UNC Lineberger Comprehensive Cancer Center

NCT02841774 COMPLETED

High Intensity Lipid Lowering Following Acute Coronary Syndromes for Persons Living With HIV

Matthew Feinstein

NCT05130086 WITHDRAWN

A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035)

Merck Sharp & Dohme LLC

NCT03308786 TERMINATED

HIV Reservoir Reduction With Interleukin-2

Case Western Reserve University

NCT04939311 WITHDRAWN

Immunomodulation Using VB-201 to Reduce Arterial Inflammation in Treated HIV - VITAL HIV Trial

Priscilla Hsue, MD

NCT05525156 SUSPENDED

The Effect of Aspirin on HIV Disease Progression Among HIV- Infected Individuals Initiating Anti- Retroviral Therapy

Muhimbili University of Health and Allied Sciences

NCT04720742 WITHDRAWN

Immune Therapy and Analytical Treatment Interruption in HIV+ Participants Who Received an Allogeneic Stem Cell Transplantation

IrsiCaixa

NCT03986970 COMPLETED

The CHAPS Trial: Combined HIV Adolescent PrEP and Prevention

Wits Health Consortium (Pty) Ltd

NCT02850016 COMPLETED

Romidepsin Plus 3BNC117 Phase 2a Study

Rockefeller University

NCT04097925 COMPLETED

Doravirine Concentrations and Antiviral Activity in Genital Fluids in HIV-1 Infected Individuals

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

NCT03550352 TERMINATED

Cannabinoids in PLWHIV on Effective ART

McGill University Health Centre/Research Institute of the McGill University Health Centre

NCT03834571 WITHDRAWN

Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women

AIDS Malignancy Consortium

NCT03743376 COMPLETED

The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients

United BioPharma

NCT03721510 COMPLETED

A Phase 1/2a Study of PGT121, VRC07-523LS and PGDM1400 Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults

International AIDS Vaccine Initiative

NCT03251144 COMPLETED

Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)

University of California, Los Angeles

NCT02915016 COMPLETED

Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03560258 COMPLETED

HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) Vaccine Study

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03787095 TERMINATED

Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02568215 COMPLETED

Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02716675 COMPLETED

Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02583048 COMPLETED

Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03296553 COMPLETED

Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.

National Institute of Cancerología

NCT05163535 COMPLETED

Open Labelled, Randomized Study to Evaluate the Efficacy, Safety and Dose Selection of VM-1500A-LAI Drug in HIV-infected Patients Transferred From Previous Stable Therapy (NNRTI + 2NRTI), Including ELPIDA®

Viriom

NCT02946047 COMPLETED

The Effect of Ixazomib on the Latent HIV Reservoir

Mayo Clinic

NCT03819114 COMPLETED

Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NCT02640625 COMPLETED

Improving Prognosis in HIV Infection

Oslo University Hospital

NCT02404311 COMPLETED

A Safety and Immune Response Study of 2 Experimental HIV Vaccines

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02194998 TERMINATED

Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02475655 COMPLETED

Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02664415 COMPLETED

Safety and Therapeutic Efficacy of the VRC01 Antibody in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02629822 COMPLETED

Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030)

Merck Sharp & Dohme LLC

NCT02624180 COMPLETED

Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV

Johns Hopkins University

NCT02178800 COMPLETED

Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03927313 COMPLETED

Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM

University of Cape Town

NCT04385719 COMPLETED

Drug-drug Interactions Between Remdesivir and Commonly Used Antiretroviral Therapy

Makerere University

NCT02440789 COMPLETED

Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART)

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NCT03081117 TERMINATED

Intranasal Insulin for the Treatment of HAND

Johns Hopkins University

NCT02588586 COMPLETED

A Study of the Safety and Antiretroviral Activity of 3BNC117

Rockefeller University

NCT03525730 COMPLETED

LRAs United as a Novel Anti-HIV Strategy.

Erasmus Medical Center

NCT02212379 COMPLETED

Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL

ANRS, Emerging Infectious Diseases

NCT03593538 COMPLETED

Effects of Metformin During Nicotine Withdrawal

University of Pennsylvania

NCT03549689 WITHDRAWN

Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)

Philip Grant

NCT03784079 COMPLETED

A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults

ViiV Healthcare

NCT03472326 TERMINATED

Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus

Gilead Sciences

NCT02566707 TERMINATED

Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen

Radboud University Medical Center

NCT03262441 COMPLETED

MMF for HIV Reservoir Reduction

Fred Hutchinson Cancer Center

NCT03891407 COMPLETED

Acceptability and Feasibility of Unsupervised HIV Self-Testing Among Networks of Men

University of South Carolina

NCT04144335 WITHDRAWN

N-803 Combined With the Broadly Neutralizing Antibodies Plus or Minus haNK Cells for HIV

University of Minnesota

NCT04557332 COMPLETED

mHealth for ART Adherence by HIV+ African Americans

Environment and Health Group, Inc.

NCT03278886 COMPLETED

St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Nalmefene

Boston Medical Center

NCT03500302 COMPLETED

Effect of Evolocumab on Coronary Endothelial Function

Johns Hopkins University

NCT02446847 COMPLETED

3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption

Rockefeller University

NCT02684591 COMPLETED

Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy

University of California, San Diego

NCT03277222 TERMINATED

Intranasal Treatment of HIV-associated Neurocognitive Disorders

University of Calgary

NCT03195452 COMPLETED

QDISS Stud: QD Isentress as Switch Strategy in Virologically Suppressed HIV-1 Infected-Patient

Nantes University Hospital

NCT03312244 SUSPENDED

Pyridostigmine as Immunomodulator in People Living With HIV

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

NCT02397694 COMPLETED

Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Gilead Sciences

NCT03045861 COMPLETED

Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults

GlaxoSmithKline

NCT03399903 COMPLETED

Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection

AIDS Healthcare Foundation

NCT02290041 COMPLETED

Treatment With MSC in HIV-infected Patients With Controlled Viremia and Immunological Discordant Response

Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud

NCT04041362 WITHDRAWN

the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients

United BioPharma

NCT02415985 COMPLETED

Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly

The HIV Netherlands Australia Thailand Research Collaboration

NCT02886624 COMPLETED

Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4

Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba

NCT02717494 COMPLETED

Safety and Immunogenicity of Anti-Pneumococcal Vaccines in HIV-Infected Pregnant Women

Westat

NCT02513901 COMPLETED

Chidamide in Combination With Antiretroviral Therapy for Eradication of the Latent HIV-1 Reservoir

Tang-Du Hospital

NCT02706717 COMPLETED

Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NCT02888756 TERMINATED

iHIVARNA Clinical Trial in HIV Infected Individuals

Rob Gruters

NCT03112031 COMPLETED

Treatment With Tamoxifen in Cryptococcal Meningitis

Oxford University Clinical Research Unit, Vietnam

NCT02750059 COMPLETED

Using Telmisartan With ART During Acute HIV Infection to Reduce the CNS Reservoirs of HIV and Lymph Node Fibrosis

SEARCH Research Foundation

NCT02339415 COMPLETED

Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease

Hennepin Healthcare Research Institute

NCT03224338 COMPLETED

Dolutegravir Plus 2 NRTIs, in Treatment-Naïve HIV-2 Infected Subjects

Blueclinical, Ltd.

NCT02972450 TERMINATED

An HIV Vaccine Trial in Individuals Who Started ART During Primary or Chronic Infection

ANRS, Emerging Infectious Diseases

NCT02412436 COMPLETED

PK Study of Rifampicin Interactions With DMPA and Efavirenz in TB

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NCT03426592 COMPLETED

Effect of High Dose Vitamin D Supplementation on HIV Latency

University of Melbourne

NCT02394730 COMPLETED

Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints

Kirby Institute

NCT01838915 COMPLETED

Randomized Placebo-controlled Pilot Trial of Prebiotics+Glutamine in HIV Infection

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

NCT03163784 WITHDRAWN

SHIFT: Studying HIV Immunology After Fecal Transplant

Massachusetts General Hospital

NCT03008941 COMPLETED

Microbiota Restoration Therapy in HIV With Repeated Low-Dose Interventions

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

NCT02559414 COMPLETED

Antiplatelet Therapy in HIV

NYU Langone Health

NCT02415595 TERMINATED

Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults

ViiV Healthcare

NCT02473328 COMPLETED

Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients

Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida

NCT02386098 TERMINATED

Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults

ViiV Healthcare

NCT02513771 COMPLETED

Sitagliptin for Reducing Inflammation and Immune Activation

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NCT02582684 COMPLETED

Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NCT02605304 TERMINATED

12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NCT02306070 WITHDRAWN

Improving Fibrosis Outcomes With Metformin

Ottawa Hospital Research Institute

NCT02441244 TERMINATED

Probiotic Visbiome for Inflammation and Translocation in HIV Ι

University Health Network, Toronto

NCT02578706 COMPLETED

Targeting Platelets in Chronic HIV Infection

Icahn School of Medicine at Mount Sinai

NCT02405013 COMPLETED

Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa

ANRS, Emerging Infectious Diseases

NCT02588547 COMPLETED

Prevention of Spinal Induced Shivering During CS

Assiut University

NCT02556333 TERMINATED

Emtricitabine/Tenofovir Alafenamide as Salvage ART

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02589678 COMPLETED

Zambia SiVET MMR Tdap-IPV

Emory University

NCT02572947 COMPLETED

A Pilot Study of MONOtherapy of DOlutegravir in HIV-1 Virologically Suppressed Patients

Calmy Alexandra

NCT02369146 COMPLETED

To Investigate the Safety and Efficacy of UB-421 Monotherapy in HIV Infected Adults

United BioPharma

NCT03316534 COMPLETED

Effect of Aspirin on Abacavir-induced Platelet Reactivity in HIV-infected Patients

Azienda Ospedaliera di Perugia

NCT03074786 WITHDRAWN

Reversing the Epidemic in Africa With Choices in HIV Prevention (REACH)

International Partnership for Microbicides, Inc.

NCT02651376 COMPLETED

Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients

Beijing 302 Hospital

NCT02527096 COMPLETED

A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol)

ANRS, Emerging Infectious Diseases

NCT02443935 COMPLETED

Toll-like Receptor 9 Agonist Treatment in Chronic HIV-1 Infection

University of Aarhus

NCT02146027 COMPLETED

Once a Day Use of Lactobacillus Casei Shirota on HIV-infected Patients Infected Patients

University of Sao Paulo General Hospital

NCT02384967 COMPLETED

Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 Patients

ANRS, Emerging Infectious Diseases

NCT02457689 COMPLETED

The Safety and Immunogenicity of the DNA-GTU Vaccine Administered to HIV-infected Patients on ART vs Placebo

Imperial College London

NCT02619019 COMPLETED

Effect of Spinal Dexamethasone During Transuretheral Prostatectomy

Assiut University

NCT02452242 COMPLETED

Safety, PK and PD Study of ABX464 in Untreated HIV Patients

Abivax S.A.

NCT02401269 COMPLETED

Cardiovascular Risk in HIV Patients on Antiretroviral Therapy Therapy: The MHEART Study

University of Pittsburgh

NCT02462772 WITHDRAWN

Safety and Acceptability of Cabotegravir in HIV Uninfected Women in KwaZulu-Natal, South Africa

Centre for the AIDS Programme of Research in South Africa

NCT02137564 WITHDRAWN

Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma

AIDS Malignancy Consortium

NCT06819176 RECRUITING

Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04514484 ACTIVE NOT RECRUITING

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

National Cancer Institute (NCI)

NCT05612178 ACTIVE NOT RECRUITING

A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy

National Institute of Allergy and Infectious Diseases (NIAID)

NCT07342491 NOT YET RECRUITING

Dasatinib for HIV-1 Reservoir Reduction

National Institute of Allergy and Infectious Diseases (NIAID)

NCT07443228 NOT YET RECRUITING

Recombinant Human Interleukin-7 (JL18008) for the Treatment of HIV-Infected Immunological Non-Responders

Jecho Biopharmaceuticals Co., Ltd.

NCT06580587 ACTIVE NOT RECRUITING

A Study of MK-8527 in Healthy Lactating Female Participants (MK-8527-009)

Merck Sharp & Dohme LLC

NCT06694753 RECRUITING

Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall Good Health in South Africa.

International AIDS Vaccine Initiative

NCT07390955 NOT YET RECRUITING

A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1

National Institute of Allergy and Infectious Diseases (NIAID)

NCT07392372 RECRUITING

A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV

BioNTech SE

NCT07042945 RECRUITING

MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003)

Merck Sharp & Dohme LLC

NCT06665646 RECRUITING

Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706

National Institute of Allergy and Infectious Diseases (NIAID)

NCT07349758 RECRUITING

Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy Volunteers

Johns Hopkins University

NCT06617091 RECRUITING

A Trial of a Gorilla Adenovirus Vectored Networked Epitopes Vaccine, Administered to Healthy Adults Living Without and With HIV.

International AIDS Vaccine Initiative

NCT05077527 RECRUITING

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

AIDS Malignancy Consortium

NCT07055451 RECRUITING

Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV

Gilead Sciences

NCT07390474 NOT YET RECRUITING

Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA in Adult Participants Without HIV

National Institute of Allergy and Infectious Diseases (NIAID)

NCT07181486 RECRUITING

Safety Study of MucoCept-CVN

Craig Cohen, MD, MPH

NCT05471076 ACTIVE NOT RECRUITING

Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b and Optional Boost Regimen With HIV Trimer BG505 SOSIP.GT1.1 gp140, Both Adjuvanted With 3M-052-AF + Alum in Healthy, Adult Participants Without HIV

National Institute of Allergy and Infectious Diseases (NIAID)

NCT06517693 RECRUITING

Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1

National Institute of Allergy and Infectious Diseases (NIAID)

NCT06585891 ACTIVE NOT RECRUITING

Study of a Human Bispecific Antibody VRC-HIVMAB0121-00-AB (CAP256J3LS) Administered Intravenously or Subcutaneously to Healthy Adults

National Institute of Allergy and Infectious Diseases (NIAID)

NCT07001319 RECRUITING

Study of GS-3242 in Participants With HIV-1; Substudy-05

Gilead Sciences

NCT06908083 ENROLLING BY INVITATION

Immunologic and Virologic Parameters During Analytical Treatment Interruption Following Combination bNAb Therapy During Suppressive ART

National Institute of Allergy and Infectious Diseases (NIAID)

NCT06513819 RECRUITING

HIV and Alcohol Research Center Focused on Polypharmacy (HARP) Pilot 2 (2nd HARP Pilot Intervention)

Yale University

NCT06033209 ACTIVE NOT RECRUITING

A Trial to Evaluate an HIV Envelope Trimer, N332-GT5 gp140, Adjuvanted With SMNP in Adult Participants Without HIV

National Institute of Allergy and Infectious Diseases (NIAID)

NCT06557785 ACTIVE NOT RECRUITING

A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIV

National Institute of Allergy and Infectious Diseases (NIAID)

NCT06006546 ACTIVE NOT RECRUITING

The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05903339 ACTIVE NOT RECRUITING

Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIV

National Institute of Allergy and Infectious Diseases (NIAID)

NCT07053384 RECRUITING

A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV

ViiV Healthcare

NCT05418868 RECRUITING

A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants

ViiV Healthcare

NCT06919016 ACTIVE NOT RECRUITING

A Study to Evaluate the Safety and Immunogenicity of the V3-region Directed Immunogens DV700P-RNA Followed by DV701B1.1-RNA in Adults Without HIV

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05245292 ACTIVE NOT RECRUITING

3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)

Rockefeller University

NCT07279129 NOT YET RECRUITING

Decision Support Tool to Integrate PrEP Into Emergency Departments

George Washington University

NCT07217379 RECRUITING

The DART DELIVER-02 Study

University of North Carolina, Chapel Hill

NCT06613789 NOT YET RECRUITING

Safety & Immunogenicity of 426c.Mod.Core-C4b Vaccine With 3M-052-AF+Alum in Infants Perinatally Exposed to HIV But Uninfected

HIV Vaccine Trials Network

NCT05069688 RECRUITING

Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin

Brigham and Women's Hospital

NCT06970223 ACTIVE NOT RECRUITING

A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV

ViiV Healthcare

NCT01961063 ACTIVE NOT RECRUITING

Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma

City of Hope Medical Center

NCT06987318 NOT YET RECRUITING

A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection

National Institute of Allergy and Infectious Diseases (NIAID)

NCT07066722 RECRUITING

A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults

ViiV Healthcare

NCT02337985 ACTIVE NOT RECRUITING

Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma

City of Hope Medical Center

NCT06034314 ACTIVE NOT RECRUITING

Oral Dronabinol-HIV

Yale University

NCT06724640 RECRUITING

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIV

ViiV Healthcare

NCT05217641 ACTIVE NOT RECRUITING

A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02500849 ACTIVE NOT RECRUITING

Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients

City of Hope Medical Center

NCT06205056 RECRUITING

Evaluation of Safety and Immunogenicity of Ad26.Mos4.HIV and CH505 TF chTrimer Combination in Healthy Adults

U.S. Army Medical Research and Development Command

NCT06796686 RECRUITING

Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health

National Institute of Allergy and Infectious Diseases (NIAID)

NCT06484335 RECRUITING

RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV

Henry M. Jackson Foundation for the Advancement of Military Medicine

NCT03617198 ACTIVE NOT RECRUITING

CD4 CAR+ ZFN-modified T Cells in HIV Therapy

University of Pennsylvania

NCT06012136 ACTIVE NOT RECRUITING

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults

ViiV Healthcare

NCT06031272 ACTIVE NOT RECRUITING

Pausing Antiretroviral Treatment Under Structured Evaluation

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NCT06652958 RECRUITING

A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV

ViiV Healthcare

NCT06233331 NOT YET RECRUITING

Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV

Emory University

NCT06786520 ACTIVE NOT RECRUITING

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults

ViiV Healthcare

NCT03729752 RECRUITING

PET Imaging of Radiolabeled Anti-HIV-1 Envelope Monoclonal Antibody (VRC01)

University of California, San Francisco

NCT06253533 ACTIVE NOT RECRUITING

ICVAX as a HIV Therapeutic DNA Vaccine

Immuno Cure Holding (HK) Limited

NCT03374202 ACTIVE NOT RECRUITING

Safety and Tolerability of AAV8 Delivery of a Broadly Neutralizing Antibody in Adults Living With HIV: a Phase 1, Dose-escalation Trial

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05890963 ACTIVE NOT RECRUITING

10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults

David Ho

NCT04340596 ACTIVE NOT RECRUITING

Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

National Institute of Allergy and Infectious Diseases (NIAID)

NCT06880380 NOT YET RECRUITING

The Efficacy and Safety Study of CAR-T Cells for Functional Cure in HIV-1/AIDS Patients

Institute of Hematology & Blood Diseases Hospital, China

NCT06310551 RECRUITING

First Time in Human Study of Long Acting VH4524184 Formulations

ViiV Healthcare

NCT06281834 RECRUITING

Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention

Brigham and Women's Hospital

NCT06332339 ACTIVE NOT RECRUITING

Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV.

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05983874 ENROLLING BY INVITATION

A Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted

International AIDS Vaccine Initiative

NCT05143307 ENROLLING BY INVITATION

Long-Term Follow-Up Study of HIV-1 Infected Adults Who Received EBT-101

Excision BioTherapeutics

NCT05001373 ACTIVE NOT RECRUITING

A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)

International AIDS Vaccine Initiative

NCT03240328 RECRUITING

The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function

Guangzhou 8th People's Hospital

NCT06680479 SUSPENDED

Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05854381 COMPLETED

To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04920539 COMPLETED

In Vivo Study of THC-induced Immune-genome Changes at Single Cell Solution in HIV-infected Humans

Yale University

NCT04915768 COMPLETED

Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05423418 COMPLETED

Safety, Tolerability, and Immunogenicity of ALFQ in a HIV Vaccine Containing A244 and B.65321 in Healthy Adults

U.S. Army Medical Research and Development Command

NCT06033547 COMPLETED

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult Participants

ViiV Healthcare

NCT04607408 COMPLETED

Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants

HIV Vaccine Trials Network

NCT05230368 COMPLETED

Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load

ANRS, Emerging Infectious Diseases

NCT04985760 COMPLETED

Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy

Madhu Chhanda Choudhary

NCT02408861 TERMINATED

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

NCT05631704 COMPLETED

A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity

ViiV Healthcare

NCT05182125 COMPLETED

Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 Chimp Adenovirus Vaccines Expressing Clade C gp140 & CH505TF gp120 Protein Boost in HIV-uninfected Adult.

HIV Vaccine Trials Network

NCT02591420 COMPLETED

Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection

National Institute of Allergy and Infectious Diseases (NIAID)

NCT06430905 TERMINATED

Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART

Hookipa Biotech GmbH

NCT05781542 COMPLETED

Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03670355 COMPLETED

Pharmacokinetic and Safety Study of a 90 Day Intravaginal Ring Containing Tenofovir

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03758625 COMPLETED

Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure

Sharon Riddler

NCT07115368 TERMINATED

Study of GS-1219 in Participants With HIV-1

Gilead Sciences

NCT03239899 COMPLETED

PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection

National Institute of Neurological Disorders and Stroke (NINDS)

NCT03526848 COMPLETED

3BNC117 and 10-1074 in ART-treated Individuals

Rockefeller University

NCT03934541 COMPLETED

Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants

National Institute of Allergy and Infectious Diseases (NIAID)

NCT06905275 SUSPENDED

A Clinical Trial to Evaluate the Safety and Immunogenicity of Glycan-trimmed HIV-1 Nanoparticle Vaccine (UVAX-1107), Followed by Homologous or Wild-type HIV-1 Nanoparticle Vaccine (UVAX-1197) Boost, Each Adjuvanted With 3M-052-AF + Alum in Adult Participants Without HIV

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05828095 COMPLETED

A Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding a Native-like HIV Env Trimer and Interleukin-12 (INO-6160), Alone or in a Prime-boost Regimen With 3M-052-AF + Alum Adjuvanted VRC HIV Env Trimer 4571 in Adult Participants Without HIV

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04177355 COMPLETED

Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05406583 COMPLETED

A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05604209 COMPLETED

Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3M4 in Persons With HIV-1 Suppressed on ART

University of North Carolina, Chapel Hill

NCT02413645 COMPLETED

Phase I, Open Label Dose Escalation Study to Evaluate Safety of iHIVARNA-01 in Chronically HIV-infected Patients

Judit Pich Martínez

NCT05627258 COMPLETED

A Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRCHIVMAB0115-00-AB (VRC01.23LS), Administered Intravenously or Subcutaneously to Healthy Adults

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04301154 COMPLETED

Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth

Henry M. Jackson Foundation for the Advancement of Military Medicine

NCT05163522 COMPLETED

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants

ViiV Healthcare

NCT04658667 COMPLETED

HIV Vaccine in HIV-uninfected Adults

U.S. Army Medical Research and Development Command

NCT04515641 COMPLETED

Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)

Merck Sharp & Dohme LLC

NCT04493684 COMPLETED

GSK3739937 First-Time-In-Human (FTIH) Study in Healthy Volunteers

ViiV Healthcare

NCT04760691 COMPLETED

Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW

Johns Hopkins University

NCT05869864 COMPLETED

Schools Championing Safe South Africa

Brown University

NCT03735849 COMPLETED

Evaluating the Safety and Pharmacokinetics of VRC07-523LS in the Sera and Mucosae of Healthy, HIV-Uninfected Adult Participants

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04900974 COMPLETED

Single Dose Pharmacokinetics of Doravirine in HIV-infected Pregnant Women

University of North Carolina, Chapel Hill

NCT05585307 COMPLETED

Study of Novel Antiretrovirals in Participants With HIV-1

Gilead Sciences

NCT04586673 COMPLETED

A Study to Assess Safety and Immunogenicity of Conserved Mosaic HIV-1 Vaccines

University of Oxford

NCT03485963 COMPLETED

HIV-1 Specific T -Cells (HST-NEETs) for HIV-Infected Individuals

Catherine Bollard

NCT06533280 WITHDRAWN

VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)

ViiV Healthcare

NCT05393271 COMPLETED

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants

ViiV Healthcare

NCT05261191 COMPLETED

A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy

MacroGenics

NCT04826094 COMPLETED

A Study to Assess the Safety and Immune Response to Env-C DNA and Protein Vaccines in Kenya

National Institute of Allergy and Infectious Diseases (NIAID)

NCT06267872 WITHDRAWN

A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05494736 COMPLETED

MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004)

Merck Sharp & Dohme LLC

NCT04283656 COMPLETED

Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women

Thomas Jefferson University

NCT05470400 COMPLETED

A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy Adults

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03157167 COMPLETED

An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)

Navidea Biopharmaceuticals

NCT06368986 COMPLETED

A Study to Investigate the Effect of Food on the Bioavailability of a Capsid Inhibitor (CAI) in Male and Female Healthy Participants

ViiV Healthcare

NCT05184452 COMPLETED

A Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of PGDM1400LS Alone and in Combination With VRC07-523LS and PGT121.414.LS in Healthy, HIV-uninfected Adult Participants

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03307915 COMPLETED

A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment

Janssen Vaccines & Prevention B.V.

NCT02589795 COMPLETED

Safety and Immunogenicity of HIV DNA-C CN54ENV and Recombinant HIV CN54gp140 Vaccines in Healthy Volunteers

Imperial College London

NCT02840474 COMPLETED

Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04568603 COMPLETED

Islatravir and Methadone Pharmacokinetics (MK-8591-029)

Merck Sharp & Dohme LLC

NCT04811040 COMPLETED

Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

Gilead Sciences

NCT06783192 COMPLETED

A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)

Merck Sharp & Dohme LLC

NCT03367754 TERMINATED

A Single Dose of Pembrolizumab in HIV-Infected People

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04212091 COMPLETED

Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05850728 COMPLETED

First in Human Study of TLC-ART 101 (ACTU 2001)

University of Washington

NCT06310616 COMPLETED

A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female Participants

ViiV Healthcare

NCT04950530 COMPLETED

The Effect of Biktarvy (B/F/TAF) on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers

Chelsea and Westminster NHS Foundation Trust

NCT04224701 COMPLETED

A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 Gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults

International AIDS Vaccine Initiative

NCT05458102 TERMINATED

Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels

Gilead Sciences

NCT05144386 COMPLETED

Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART

Excision BioTherapeutics

NCT04058392 COMPLETED

Camu Camu in ART-treated People Living with HIV

McGill University Health Centre/Research Institute of the McGill University Health Centre

NCT06318546 COMPLETED

Dexmedetomidine in Spinal Anesthesia Decreasing Post Spinal Shivering in Caesarean Section

Ain Shams University

NCT03816137 COMPLETED

Modelling the Interaction Between Rationally-designed Synthetic Model Viral Protein Immunogens

Imperial College London

NCT03408262 COMPLETED

Clinical Trial of HIV Vaccine Combinations in Healthy Men and Women

Imperial College London

NCT04833127 COMPLETED

A Gender-Enhanced Pre-Exposure Prophylaxis (PrEP) Information-Motivational Workshop for Young South African Women

New York State Psychiatric Institute

NCT03894124 COMPLETED

Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers

Chelsea and Westminster NHS Foundation Trust

NCT05291520 COMPLETED

A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult Participants

ViiV Healthcare

NCT04630002 COMPLETED

Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)

ViiV Healthcare

NCT05362955 COMPLETED

5-fluorouracil Following Cervical Intraepithelial Neoplasia Treatment Among HIV-positive Women in East Africa

UNC Lineberger Comprehensive Cancer Center

NCT05933824 COMPLETED

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LP-98 Injection in Healthy Subjects

Shanxi Kangbao Biological Product Co., Ltd.

NCT02595866 COMPLETED

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

National Cancer Institute (NCI)

NCT06168318 COMPLETED

A Study to Investigate the Relative Bioavailability and Food Effect of an Oral Capsid Inhibitor Tablet Formulation Compared With Other Oral Tablet Formulations in Male and Female Healthy Participants

ViiV Healthcare

NCT03856996 COMPLETED

A Clinical Trial in Healthy, HIV-1-Uninfected Adult Participants to Compare the Safety, Tolerability and Immunogenicity of CH505TF gp120 Produced From Stably Transfected Cells to CH505TF gp120 Produced From Transiently Transfected Cells

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05959707 SUSPENDED

Evaluating the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibodies in Healthy Participants

HIV Vaccine Trials Network

NCT05416021 COMPLETED

Relative Bioavailability Trial of Dapivirine Ring-004 and Ring-008

International Partnership for Microbicides, Inc.

NCT04893018 TERMINATED

NT-I7 for Kaposi Sarcoma in Patients With or Without HIV

Fred Hutchinson Cancer Center

NCT03960645 COMPLETED

Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters

Gilead Sciences

NCT06450275 COMPLETED

Bioequivalence Study to Compare Dolutegravir 50mg Film-coated Tablets

Humanis Saglık Anonim Sirketi

NCT03220724 COMPLETED

Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02616874 COMPLETED

Study to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals

IrsiCaixa

NCT05208125 COMPLETED

A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines ChAdOx1.HTI and MVA.HTI With Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 gp140 Vaccine, Adjuvanted With MPLA Liposomes in ART-Suppressed HIV-1 Positive Individuals

IrsiCaixa

NCT05769569 WITHDRAWN

Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission

Henry M. Jackson Foundation for the Advancement of Military Medicine

NCT05944848 COMPLETED

A Study of CL-197 Capsules in Healthy Participants

Henan Genuine Biotech Co., Ltd.

NCT04371380 COMPLETED

Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants

ViiV Healthcare

NCT02531295 TERMINATED

Immunologic Response to Kansui in Treated HIV+ Individuals: a Dose Escalation Study

University of California, San Francisco

NCT04927585 COMPLETED

Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults

Worcester HIV Vaccine

NCT04808908 COMPLETED

Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV Disease

University of Minnesota

NCT02797171 COMPLETED

Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02771730 TERMINATED

Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults

Emergent BioSolutions

NCT04857892 COMPLETED

A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants

ViiV Healthcare

NCT04554966 COMPLETED

Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)

AbbVie

NCT05700630 WITHDRAWN

Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia

Masonic Cancer Center, University of Minnesota

NCT03181789 COMPLETED

Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02750540 COMPLETED

Optimization of a Tenofovir Enema for HIV Prevention

Johns Hopkins University

NCT03538626 COMPLETED

Phase I, Open-Label, Dose-Escalation Study of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03705169 TERMINATED

Pharmacokinetics and Safety of SAR441236

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04408963 COMPLETED

A Phase 1 Trial to Evaluate CAP256V2LS in Healthy Adults

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04425902 COMPLETED

Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults

ViiV Healthcare

NCT04047420 COMPLETED

Safety and Pharmacokinetic Study of Tenofovir Alafenamide (TAF)/Elvitegravir (EVG) Administered Rectally

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03699241 COMPLETED

A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults

International AIDS Vaccine Initiative

NCT05776108 COMPLETED

A Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispersible Tablet (DT) Formulation

ViiV Healthcare

NCT04563845 COMPLETED

Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin

ViiV Healthcare

NCT05489406 COMPLETED

Relative Bioavailability Study to Investigate a Potential Interaction Between DTG DT and F/TAF TOS.

Radboud University Medical Center

NCT04484337 COMPLETED

Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants

ViiV Healthcare

NCT02579083 COMPLETED

Safety Study of Monoclonal Antibodies to Reduce the Vaginal Transmission of HSV and HIV

KBio Inc

NCT04686279 COMPLETED

Tenofovir Rectal Douche to Prevent HIV Transmission Among Adolescents (ATN DREAM)

University of Pennsylvania

NCT05349968 COMPLETED

Pharmacokinetics and Efficacy of Multiple Dosing of Lipovirtide for Injection in HIV-infected Patients

Shanxi Kangbao Biological Product Co., Ltd.

NCT04592315 COMPLETED

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lipovirtide in HIV-infected Patients

Shanxi Kangbao Biological Product Co., Ltd.

NCT03270969 COMPLETED

A Pharmacokinetic Evaluation of Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis in Transgender Women

University of Nebraska

NCT05197075 COMPLETED

A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children

Janssen Research & Development, LLC

NCT05079451 WITHDRAWN

Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04032717 TERMINATED

Griffithsin-based Rectal Microbicide for PREvention of Viral ENTry (PREVENT)

Rhonda Brand

NCT04250636 COMPLETED

3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals

Rockefeller University

NCT04827134 COMPLETED

A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants

ViiV Healthcare

NCT03212989 COMPLETED

Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on Antiretroviral Therapy (ART)

University of North Carolina, Chapel Hill

NCT04620304 COMPLETED

Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients

United BioPharma

NCT03961438 COMPLETED

Amsterdam UMC Clinical Trial With a Native-like HIV-1 Envelope Vaccine

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

NCT03408899 COMPLETED

Evaluating the Safety and Pharmacokinetics of PC-1005 Administered Rectally to HIV-1 Seronegative Adults

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03917420 COMPLETED

Quantification of Estradiol's Impact on Nucleotides in Cellular Populations of the Lower GI Tract

University of North Carolina, Chapel Hill

NCT04561258 COMPLETED

Study to Evaluate the Safety of a Gene and Cell Therapy Product in Participants With HIV That is Well-Controlled on Antiretroviral Therapy

American Gene Technologies International Inc.

NCT03387150 COMPLETED

Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05700734 WITHDRAWN

MK-8510 Monotherapy for the Treatment of Anti-retroviral naïve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8510-002)

Merck Sharp & Dohme LLC

NCT03581305 COMPLETED

PET Imaging of the Dopaminergic and Serotonergic Systems in Treated HIV Positive Subjects

National Institutes of Health Clinical Center (CC)

NCT02659306 COMPLETED

Metformin Immunotherapy in HIV Infection

McGill University Health Centre/Research Institute of the McGill University Health Centre

NCT04223804 COMPLETED

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1

AbbVie

NCT03875209 COMPLETED

10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults

David Ho

NCT04725877 COMPLETED

VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers

Vir Biotechnology, Inc.

NCT04672083 COMPLETED

A Clinical Study of the HIV Drug CPT31 in Healthy Volunteers

Navigen, Inc.

NCT05165550 COMPLETED

Study of Single Ascending Doses of Elsulfavirine to Evaluate the Safety, Tolerability, and Pharmacokinetics of Elsulfavirine and Its Active Metabolite VM-1500A in Healthy Subjects

Viriom

NCT05244473 WITHDRAWN

A Safety Study of Brentuximab Vedotin in Participants With HIV

Seagen Inc.

NCT02256631 COMPLETED

Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04195776 COMPLETED

Evaluating Distribution of a Tenofovir Douche With Tap Water Douching and Simulated Receptive Anal Intercourse

Johns Hopkins University

NCT05206019 COMPLETED

Study to Evaluate Pharmacokinetic and Safety of Albuvirtide Between Intravenous Drip and Intravenous Injection

Frontier Biotechnologies Inc.

NCT04799353 COMPLETED

Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV)

AbbVie

NCT03570918 COMPLETED

MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy

MacroGenics

NCT03844386 COMPLETED

Study to Assess Safety and Ability to Induce Immune Responses of HIV-1 Vaccines M3 and M4 Given Alone or in Combination in HIV-infected Adults

University of North Carolina, Chapel Hill

NCT02852005 COMPLETED

Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03928821 COMPLETED

Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult Participants

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04424264 COMPLETED

The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants

Professor Francois Venter

NCT03547245 COMPLETED

A Phase I Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted

International AIDS Vaccine Initiative

NCT04385875 COMPLETED

Study to Assess the Safety and Durability of Viral Control Beyond 24 Weeks of Analytical Treatment Interruption After the Administration of Candidate HIV-1 Vaccines DNA.HTI, MVA.HTI and ChAdOx1.HTI or Placebo in Early Treated HIV-1 Positive Individuals (ATI Extension of AELIX-002 Study)

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

NCT03409276 COMPLETED

Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03834909 WITHDRAWN

Pre-Exposure Prophylaxis Dosing in Pregnancy to Optimize HIV Prevention (PREP-P)

Johns Hopkins University

NCT03571204 TERMINATED

Combination Therapy With 3BNC117 and 10-1074 in HIV-Infected Individuals

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03618056 COMPLETED

Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04507321 COMPLETED

Pharmacokinetics and Metabolism of 14 Carbon [14C]-GSK3640254

ViiV Healthcare

NCT03709355 COMPLETED

Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs

Viriom

NCT05204121 COMPLETED

Phase Ib Study of Safety, Tolerability and Pharmacokinetics of Elpida Once Weekly in Healthy Volunteers

Viriom

NCT03706898 COMPLETED

Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral Drugs

Viriom

NCT02778204 COMPLETED

Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04802811 COMPLETED

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics ，Pharmacodynamics of Oral SHR2150 in Healthy Subjects

Jiangsu HengRui Medicine Co., Ltd.

NCT03837015 COMPLETED

Estrogen, Probiotics and Vaginal Health to Prevent HIV Infection in ACB Women

McMaster University

NCT02756208 COMPLETED

A Safety and Immunogenicity Trial of IHV01

University of Maryland, Baltimore

NCT03706911 COMPLETED

Study to Evaluate Safety, Tolerability and Pharmacokinetics of VM-1500A-LAI Single and Multiple Ascending Doses in Healthy Subjects

Viriom

NCT05148754 COMPLETED

An Open-label Clinical Study of the Pharmacokinetics and Safety of Elsulfavirine, 200 mg Tablets, With Single and Multiple Oral Administration in Healthy Volunteers

Viriom

NCT03803605 COMPLETED

Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons

University of North Carolina, Chapel Hill

NCT02419456 COMPLETED

Pharmacokinetics of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02411539 COMPLETED

Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04035759 COMPLETED

Positive Affect Promotion to Empower Optimal Adherence to HIV Therapy

State University of New York - Downstate Medical Center

NCT04303156 COMPLETED

Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)

Merck Sharp & Dohme LLC

NCT03984812 TERMINATED

Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study

ViiV Healthcare

NCT02356302 COMPLETED

Safety and Pharmacokinetics of Intravaginal Rings Containing Vicriviroc (MK-4176) and/or MK-2048

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03393468 COMPLETED

Pharmacokinetic Study of Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02463227 COMPLETED

Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03239483 COMPLETED

Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04041674 WITHDRAWN

Evaluating the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120 and IHV01 gp120 Env Proteins in Healthy, HIV-uninfected Adult Participants

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03505060 WITHDRAWN

Evaluating the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-Administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected Adults

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02431767 COMPLETED

Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02654080 COMPLETED

Evaluating the Safety, Tolerability, and Immunogenicity of a Prime-Boost Regimen of HIV-1 Nef/Tat/Vif, Env pDNA Vaccine Delivered Intramuscularly With Electroporation and HIV-1 rVSV envC Vaccine in Healthy, HIV-Uninfected Adults

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03831945 TERMINATED

Combination Therapy With VRC01 and 10-1074 in HIV-Infected Individuals Undergoing Sequential Treatment Interruptions

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03382418 COMPLETED

Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04027387 COMPLETED

Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants

TaiMed Biologics Inc.

NCT04757974 COMPLETED

Low-dose Fostemsavir Extended Release Relative Bioavailability Study

ViiV Healthcare

NCT03976752 COMPLETED

Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens

Emory University

NCT03783130 COMPLETED

Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03554408 COMPLETED

First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS

Rockefeller University

NCT03293290 COMPLETED

Project EMPOWERING: Evidence-based PrEP for Justice-Involved Women and Their Risk Networks

Yale University

NCT03980691 COMPLETED

Effect of Chidamide Combined With CAT-T or TCR-T Cell Therapy on HIV-1 Latent Reservoir

Guangzhou 8th People's Hospital

NCT04006704 COMPLETED

Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets

Janssen Pharmaceutica N.V., Belgium

NCT03231943 COMPLETED

GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers

ViiV Healthcare

NCT04016233 COMPLETED

Tenofovir Rectal Douche to Prevent HIV Transmission

Johns Hopkins University

NCT03859739 COMPLETED

Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002)

Merck Sharp & Dohme LLC

NCT03422172 COMPLETED

A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese Men

ViiV Healthcare

NCT03899480 COMPLETED

Adoptive Transfer of Haploidentical NK Cells and N-803

University of Minnesota

NCT03060447 COMPLETED

Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers

Gilead Sciences

NCT03270709 TERMINATED

Effect of High-Dose Vitamin D3 in Smokers and Non-Smokers With and Without HIV

Emory University

NCT03739866 COMPLETED

Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults

Gilead Sciences

NCT03204617 COMPLETED

Safety and Immunogenicity Study of DNA.HTI, MVA.HTI and ChAdOx1.HTI in HIV-1-positive Patients (AELIX-002)

Aelix Therapeutics

NCT02325934 COMPLETED

Bioequivalence of Crushed Stribild With a Normal Breakfast or With Drip Feed Compared to the Whole Tablet

Radboud University Medical Center

NCT04263142 COMPLETED

A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants

ViiV Healthcare

NCT03254277 COMPLETED

3BNC117-LS First-in-Human Phase 1 Study

Rockefeller University

NCT03663998 COMPLETED

Optimising DNA Vaccinations in Healthy Volunteers

Imperial College London

NCT03697226 COMPLETED

Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection.

Antiva Biosciences

NCT02549040 COMPLETED

Bioavailability of Doravirine (MK-1439) Experimental Nano Formulations in Healthy Adults (MK-1439-046)

Merck Sharp & Dohme LLC

NCT02565888 COMPLETED

A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat

Radboud University Medical Center

NCT02569346 COMPLETED

Bioequivalence Study of CRushed TriUMeq With or Without Drip Feed Compared to the Whole Tablet

Radboud University Medical Center

NCT03234036 COMPLETED

A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir

GlaxoSmithKline

NCT03015181 COMPLETED

VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy Adults

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03368053 COMPLETED

Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461)

GlaxoSmithKline

NCT03615183 COMPLETED

A Study of MK-8527 in Human Immunodeficiency Type 1 Virus (HIV-1) Infected Participants (MK-8527-002)

Merck Sharp & Dohme LLC

NCT03149848 COMPLETED

Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects

ViiV Healthcare

NCT03205917 COMPLETED

A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults

International AIDS Vaccine Initiative

NCT02354937 COMPLETED

Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment

ViiV Healthcare

NCT03472963 COMPLETED

Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis.

Emory University

NCT03984825 COMPLETED

Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive

ViiV Healthcare

NCT04128293 TERMINATED

A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants

ViiV Healthcare

NCT02354950 COMPLETED

A Study to Evaluate Pharmacokinetic (PK) and Safety of GSK1265744 in Subjects With Hepatic Impairment and Control Healthy Volunteers

ViiV Healthcare

NCT03921723 COMPLETED

Dolutegravir Pediatric Liquid Formulation Study

ViiV Healthcare

NCT04322214 COMPLETED

Clinical Trial to Evaluate Pharmacological Interactions Between γ-hydroxybutyrate (GHB) and Cobicistat

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

NCT03719053 COMPLETED

Single Dose Truvada Study

Johns Hopkins University

NCT03984838 COMPLETED

Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese Descent

ViiV Healthcare

NCT03063788 COMPLETED

Imaging the HIV Reservoir

Bayside Health

NCT02478463 COMPLETED

Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers

ViiV Healthcare

NCT03329560 COMPLETED

Safety of FMT Using Oral Encapsulated PRIM-DJ2727 in HIV

The University of Texas Health Science Center, Houston

NCT03110549 TERMINATED

Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers

TaiMed Biologics Inc.

NCT03836729 COMPLETED

Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide/Emtricitabine

ViiV Healthcare

NCT03886701 COMPLETED

Doravirine, Rifapentine and Isoniazid Interaction

Walter K. Kraft

NCT03816696 COMPLETED

Study to Evaluate the Pharmacokinetic (PK) Interactions Between GSK3640254 and Dolutegravir (DTG)

ViiV Healthcare

NCT02170246 COMPLETED

Analysis of Telmisartan Administered With Antiretroviral Therapy (ART) in Patients With Acute HIV Infection

Yale University

NCT03552536 COMPLETED

MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002)

Merck Sharp & Dohme LLC

NCT03753867 WITHDRAWN

RA Effect on Cell Surface Molecules in Vivo

Ottawa Hospital Research Institute

NCT02788175 COMPLETED

Vedolizumab (Anti-alpha4beta7) in Subjects With HIV Infection Undergoing Analytical Treatment Interruption

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02858401 COMPLETED

Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults

Gilead Sciences

NCT02191098 COMPLETED

Proof of Principle Study of Pulse Dosing of IL-15 to Deplete the Reservoir in HIV Infected People

University of Minnesota

NCT02599896 COMPLETED

Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03441984 COMPLETED

To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers

ViiV Healthcare

NCT02527460 TERMINATED

Anakinra, A Recombinant Human IL-1 Receptor Antagonist for Neuroinflammation in HIV-1 Infection

National Institute of Neurological Disorders and Stroke (NINDS)

NCT03346499 COMPLETED

Adoptive Transfer of Haploidentical Natural Killer Cells and IL-2

University of Minnesota

NCT03351699 COMPLETED

Single-Dose Study of MK-4250 Monotherapy in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-4250-002)

Merck Sharp & Dohme LLC

NCT03082690 COMPLETED

ImQuest (IQP) DuoGel Phase 1 Pharmacokinetic Study

Johns Hopkins University

NCT02400307 COMPLETED

Pharmacokinetics of Bictegravir in Adults With Normal and Impaired Renal Function

Gilead Sciences

NCT02707900 TERMINATED

Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection

University of North Carolina, Chapel Hill

NCT02208167 COMPLETED

Phase I Study of HIV 1 Antigen Expanded Specific T Cell Therapy

University of North Carolina, Chapel Hill

NCT02960581 COMPLETED

Safety, PK and Antiviral Activity of PGT121 Monoclonal Antibody in HIV-uninfected and HIV-infected Adults

International AIDS Vaccine Initiative

NCT02985996 COMPLETED

Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities

Emory University

NCT03289676 COMPLETED

Storytelling Narrative Communication Intervention for Smoking Cessation in Women Living With HIV

University of Massachusetts, Boston

NCT03575962 COMPLETED

A Study to Compare the Relative Bioavailability of Two Different Formulations of GSK3640254

ViiV Healthcare

NCT02217904 COMPLETED

A Study of Islatravir (MK-8591) in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus-1 Infected Participants (MK-8591-003)

Merck Sharp & Dohme LLC

NCT02767193 COMPLETED

Safety and Immunogenicity of a Vaccine Dendritic Cell-based Pulsed With Autologous Heat-inactivated in HIV-1 Infected Patients

Judit Pich Martínez

NCT03677960 TERMINATED

Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection

Antiva Biosciences

NCT03095638 COMPLETED

Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional Tablets of Dolutegravir

ViiV Healthcare

NCT03762772 COMPLETED

Safety, PK, and PD Study of a Vaginal Insert Containing TAF and EVG

CONRAD

NCT02741557 COMPLETED

Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)

ViiV Healthcare

NCT03188523 COMPLETED

Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002)

Merck Sharp & Dohme LLC

NCT02715700 COMPLETED

Effects of Doravirine (MK-1439) on Methadone Pharmacokinetics in Methadone-Maintained Participants (MK-1439-045)

Merck Sharp & Dohme LLC

NCT02997969 COMPLETED

Safety and Immune Response to a Clade C DNA HIV Vaccine

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02563509 COMPLETED

Reconstitution of HIV-specific Immunity Against HIV

Guangzhou 8th People's Hospital

NCT02993237 COMPLETED

Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets

Janssen Research & Development, LLC

NCT02388594 COMPLETED

A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients

University of Pennsylvania

NCT03892161 TERMINATED

Clinical Evaluation of Adjusted Doses of Darunavir/Ritonavir With Rifampicin in HIV-infected Volunteers

University of Cape Town

NCT03078556 COMPLETED

Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine

ViiV Healthcare

NCT03202992 COMPLETED

Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection

Antiva Biosciences

NCT03391375 COMPLETED

Evaluation of the Effect of Late Boost on HIV-uninfected Vaccines From EV06 Trial

EuroVacc Foundation

NCT03234400 COMPLETED

A Phase 1, Randomized Pharmacokinetics and Safety Study of Extended Duration Dapivirine Vaginal Rings

International Partnership for Microbicides, Inc.

NCT02378922 WITHDRAWN

Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

Fred Hutchinson Cancer Center

NCT02875119 COMPLETED

Study to Evaluate the Safety of Griffithsin in a Carrageenan Gel in Healthy Women

Population Council

NCT02343666 WITHDRAWN

HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection

Fred Hutchinson Cancer Center

NCT02547870 COMPLETED

A Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long-Acting Nanosuspension of Rilpivirine on Pharmacokinetics

Janssen Infectious Diseases BVBA

NCT03118661 WITHDRAWN

Maraviroc on HIV-1 Infected Subjects Who Require Allogeneic Hematopoietic Cell Transplant

Washington University School of Medicine

NCT02652546 COMPLETED

CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE)

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03706924 COMPLETED

Comparative Study of PK and BE of VM-1500FDC (Fixed-dose Combination) and Elpida® With Truvada® сo-administrated 1 Daily Fasting in Healthy Subjects

Viriom

NCT02473367 COMPLETED

The Effect of Antacids on the Pharmacokinetics (PK) of Raltegravir in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-824)

Merck Sharp & Dohme LLC

NCT02762617 TERMINATED

Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring (TDF IVR-002)

Marla Keller

NCT02825797 COMPLETED

3BNC117 and 10-1074 in HIV-infected Individuals

Rockefeller University

NCT03060785 COMPLETED

Finding the Right Tenofovir/Emtricitabine Regimen for Pre-Exposure Prophylaxis (PrEP) in Transgender Women

Johns Hopkins University

NCT02578277 COMPLETED

Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates

ViiV Healthcare

NCT02855346 COMPLETED

PK and Safety Study of Vaginal Rings Containing Dapivirine and Levonorgestrel

International Partnership for Microbicides, Inc.

NCT03094507 COMPLETED

The Pharmacokinetics of Dolutegravir, Darunavir/Cobocistat When Co-administered in Healthy Volunteers

St Stephens Aids Trust

NCT02674581 COMPLETED

A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)

ViiV Healthcare

NCT02824536 COMPLETED

3BNC117 and 10-1074 in HIV Uninfected Adults

Rockefeller University

NCT02608918 COMPLETED

Taste Properties of HIV Inhibitor

ViiV Healthcare

NCT02808949 COMPLETED

Pharmacokinetic Study of the Dapivirine Vaginal Ring in Lactating Women

International Partnership for Microbicides, Inc.

NCT02818348 COMPLETED

Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected Patients

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

NCT02904369 COMPLETED

PK and PD Study of Oral F/TAF for HIV Prevention

CONRAD

NCT03186482 COMPLETED

RIFT: Effect of Rifampicin on Plasma PK of FTC, TAF and Intracellular TFV-DP & FTC-TP

St. Stephens Clinical Research

NCT02511990 COMPLETED

A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074

Rockefeller University

NCT02697851 TERMINATED

Pharmacokinetic Effect of Evotaz/Microgynon Co-administration

St Stephens Aids Trust

NCT02527005 COMPLETED

A Comparative Study of Azithromycin and S-P as Prophylaxis in Pregnant HIV+ Patients

University of Ibadan

NCT02556268 COMPLETED

Interaction With HIV Antiretroviral Agents

Bayer

NCT02471326 COMPLETED

VRC-HIVMAB060-00-AB (VRC01) in People With Chronic HIV Infection Undergoing Analytical Treatment Interruption

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02499874 COMPLETED

SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women

St Stephens Aids Trust

NCT02480894 COMPLETED

A Open-label, Drug-Drug Interaction With Maraviroc (DDI)

ViiV Healthcare

NCT02467335 COMPLETED

Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects

ViiV Healthcare

NCT02508064 COMPLETED

Bioavailability of BMS-626529 in Healthy Subjects From Prototype Low Dose Extended Release Formulations (Part 1) and Prototype Extended Release Multi-particulate Formulations (Part 2) of BMS-663068 Relative to 600 mg Extended Release Tablet

ViiV Healthcare

NCT02666053 COMPLETED

A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy Subjects

ViiV Healthcare

NCT03054207 TERMINATED

Impact of Antiretroviral Treatment on Pharmacokinetics and Pharmacodynamics of Thienopyridines in Healthy Volunteers and HIV Patients

Jules Desmeules

NCT02346084 COMPLETED

Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults

International Partnership for Microbicides, Inc.

NCT02858024 COMPLETED

A Trial In Healthy HIV-Negative Women To Assess The Effect Of Menses And Tampon Use On The Pharmacokinetics Of Dapivirine, Delivered By Dapivirine Vaginal Ring-004, Containing 25 Mg Of Dapivirine

International Partnership for Microbicides, Inc.

NCT02847286 COMPLETED

To Assess the Drug-drug Interaction Potential Between Dapivirine Vaginal Ring-004, Containing 25 mg of Dapivirine, and Clotrimazole 10 mg/g (1%)

International Partnership for Microbicides, Inc.

NCT02877979 COMPLETED

Evaluate the Safety & Assess Local and Systemic PK of DS003 Vaginal Tablets Administered to Healthy HIV-negative Women

International Partnership for Microbicides, Inc.

NCT02666001 COMPLETED

A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone

ViiV Healthcare

NCT02576119 TERMINATED

A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects

ViiV Healthcare

NCT02893488 COMPLETED

Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet

ViiV Healthcare

NCT02480881 COMPLETED

A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)

ViiV Healthcare

NCT02805556 COMPLETED

Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing

ViiV Healthcare

NCT02895893 COMPLETED

PrEP SMART Phase I Trial

Duke University

NCT02859259 COMPLETED

A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects

ViiV Healthcare

NCT02812329 COMPLETED

Intervention to Encourage HIV Testing and Counseling Among Adolescents

Yale University

NCT03044379 WITHDRAWN

Dapivirine Gel Rectal Safety and PK Study

International Partnership for Microbicides, Inc.

NCT02715479 COMPLETED

A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176

ViiV Healthcare

NCT02795754 COMPLETED

Single and Repeated Dose Escalation Study of GSK2838232

GlaxoSmithKline

NCT02738931 COMPLETED

Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations

ViiV Healthcare

NCT02342223 COMPLETED

Voluma Filler Agent For The Treatment of HIV-associated Facial Lipoatrophy

Jared Jagdeo, MD, MS

NCT02799264 COMPLETED

A Study to Evaluate the Effect of High Fat Meal on Cabotegravir

ViiV Healthcare

NCT02631473 SUSPENDED

PK of Efavirenz & Lopinavir Nano-formulations in Healthy Volunteers

St Stephens Aids Trust

NCT02366013 COMPLETED

Trial of the Safety and Immunogenicity of an Oral, Replicating Ad26 Vectored HIV-1 Vaccine

International AIDS Vaccine Initiative

NCT02242799 COMPLETED

Dolutegravir Interactions With Artemisinin-based Combination Therapies

University of Liverpool

NCT02569697 COMPLETED

Development of Adherence Biomarkers for Multiple Microbicide and Multipurpose Prevention Technology (MPT) Dosage Forms

CONRAD

NCT02722343 COMPLETED

Exploratory Pharmacodynamic Study of Tenofovir-Based Products

CONRAD

NCT02373930 COMPLETED

Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects

ViiV Healthcare

NCT02456558 COMPLETED

Evaluation of the Safety, Efficacy, and Pharmacokinetics of Intravenous Deferiprone in HIV-Positive Subjects

ApoPharma

NCT02589158 COMPLETED

SSAT067 PK of Atazanavir/Cobicistat and Darunavir/Cobicistat

St Stephens Aids Trust

NCT02527941 COMPLETED

Effect of Bacterial Vaginosis on HIV Susceptibility and Female Genital Immunology

University of Toronto

NCT02411435 COMPLETED

Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects

ViiV Healthcare

NCT02539576 COMPLETED

Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects

ViiV Healthcare

NCT02345707 COMPLETED

Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir

ViiV Healthcare

NCT05393193 ACTIVE NOT RECRUITING

POC HIV Testing and Early DTG Use for Infants

Harvard School of Public Health (HSPH)

NCT05630638 RECRUITING

Doravirine Dose Optimisation in Pregnancy

University of Liverpool

NCT06854029 NOT YET RECRUITING

NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings

Duke University

NCT05495906 RECRUITING

A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIV

University of British Columbia

NCT06967519 RECRUITING

OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa

Yale University

NCT07218211 RECRUITING

Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP

Duke University

NCT06526507 ENROLLING BY INVITATION

PrEPARE-SCALE: Scaling up Integrated PrEP Delivery in Kenyan Maternal and Child Health Clinics

University of Washington

NCT07357584 NOT YET RECRUITING

Efficacy and Safety of Doravirine in the Rapid Initiation

Fundación Huésped

NCT07357103 NOT YET RECRUITING

Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)

McGill University Health Centre/Research Institute of the McGill University Health Centre

NCT06908252 RECRUITING

MAPS PrEP Van Study

Duke University

NCT06436274 ACTIVE NOT RECRUITING

Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV.

Massachusetts General Hospital

NCT07328984 NOT YET RECRUITING

How Long Should we Give Steroids for Patients With Severe PCP

McGill University Health Centre/Research Institute of the McGill University Health Centre

NCT05694637 ENROLLING BY INVITATION

Botswana Smoking and Abstinence Reinforcement Trial

University of Maryland, Baltimore

NCT05118490 ACTIVE NOT RECRUITING

Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients

The Aurum Institute NPC

NCT06337032 RECRUITING

A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

Gilead Sciences

NCT07199335 NOT YET RECRUITING

Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs

Massachusetts General Hospital

NCT07210125 RECRUITING

Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting

Kelley-Ross & Associates, Inc.

NCT07160075 RECRUITING

HIV Prevention With PrEP Among People on Opioid Replacement Therapy

Cara Spence

NCT04265950 ACTIVE NOT RECRUITING

Establishing Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIV, OPTIMO Trial

Fred Hutchinson Cancer Center

NCT06967753 RECRUITING

Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)

UBATEC

NCT04730609 RECRUITING

Dexmedetomidine for Intraoperative Shivering in Scheduled Elective Cesarean Delivery

Mayo Clinic

NCT07154849 RECRUITING

Comparative Study Between the Efficacy of Intravenous Hydrocortisone and Intravenous Dexmedetomidine for Prevention of Postoperative Shivering After General Anaesthesia for Abdominal Surgeries

Ain Shams University

NCT07138144 RECRUITING

Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-Up

José Antonio Mata Marín

NCT07110831 NOT YET RECRUITING

Disposition Kinetics of Dolutegravir Among People Living With HIV With Major Depression in Nigeria

University of Ibadan

NCT05220358 ACTIVE NOT RECRUITING

Changes in Immunologic Parameters Following the Addition of Fostemsavir in Virologically Suppressed Immunologic Non-responders Living With HIV-the RECOVER Study

Orlando Immunology Center

NCT07088601 NOT YET RECRUITING

Efficacy of Oral Ondansetron Strips on Prevention of Post-Spinal Shivering

Cairo University

NCT06474364 RECRUITING

HIV Prevention and Care Interventions for Youth in Uganda

MU-JHU CARE

NCT07076043 RECRUITING

Multi-product PrEP Delivery to Young Women Seeking Reproductive Health Services and Coverage of HIV Prevention

University of Alabama at Birmingham

NCT05537935 RECRUITING

Low Dose Naltrexone for Pain in Patients With HIV

Emory University

NCT06856174 NOT YET RECRUITING

Menopausal HT for Women Living With HIV (HoT)

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NCT07000513 NOT YET RECRUITING

HIV Self-Testing and Long-Acting Injectables for HIV Treatment and Prevention Among Commercial Minibus Drivers (I-TEST LAIs) in Nigeria

George Washington University

NCT07031063 RECRUITING

Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience

Instituto Mexicano del Seguro Social

NCT06787976 NOT YET RECRUITING

Effect of Dolutegravir Compared With Darunavir/Cobicistat on the Severity of Neuropsychiatric Effects al 12 Weeks in Antirretroviral Treatment-Naive Adults.

Instituto Mexicano del Seguro Social

NCT02656511 ACTIVE NOT RECRUITING

Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection

University of California, San Francisco

NCT06514547 RECRUITING

Vaccine Immunity and Inflammation in the Aging Person Living With HIV

Hennepin Healthcare Research Institute

NCT07006246 ACTIVE NOT RECRUITING

Utilizing Private Pharmacies to Initiate High-risk Young Individuals on PrEP in South Africa

Professor Francois Venter

NCT06598397 RECRUITING

Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care

New York University

NCT05547048 RECRUITING

Integrated e-Health (Electronic Health) for HIV and Substance Use Disorders in Justice Involved Women

Yale University

NCT06374758 RECRUITING

Accelerated ART Initiation for PWHIV Who Are Out of Care

University of Missouri-Columbia

NCT05266898 RECRUITING

Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV

Louisiana State University Health Sciences Center in New Orleans

NCT06829238 RECRUITING

Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use

University of Alabama at Birmingham

NCT06907056 RECRUITING

Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Versus Darunavir/Cobicistat Plus Tenofovir/Emtricitabine in Virologically Suppressed HIV-1-positive Individuals in Mexico

José Antonio Mata Marín

NCT05669534 RECRUITING

Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEP

University of Connecticut

NCT06158126 RECRUITING

UNCPM 22314 - Pregnancy, Infant and Maternal Health Outcomes Study

University of North Carolina, Chapel Hill

NCT06646562 RECRUITING

Long Acting Cabotegravir Plus Rilpivirine in People Living with HIV-1 Aged ≥ 60 Years for 24 Months.

Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia

NCT03391921 ACTIVE NOT RECRUITING

Vaccination Against Human Papillomavirus (HPV) With the 9-valent Vaccine in HIV-positive Women (the Papillon Study)

Centre Hospitalier Universitaire Saint Pierre

NCT06830668 NOT YET RECRUITING

Same-Day Restart of B/F/TAF in HIV Patients After NNRTI Discontinuation

National Center for AIDS/STD Control and Prevention, China CDC

NCT06037564 ENROLLING BY INVITATION

B-free Multistage Trial

Insel Gruppe AG, University Hospital Bern

NCT05663892 ACTIVE NOT RECRUITING

Drug-Drug Interaction Study in Trans Women Living With HIV

Maple Leaf Research

NCT06602622 RECRUITING

Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTI

Instituto Mexicano del Seguro Social

NCT06580873 NOT YET RECRUITING

Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT)

Saskatchewan Health Authority - Regina Area

NCT04270773 ACTIVE NOT RECRUITING

Immunogenicity and Safety of a 9-valent Human Papillomavirus Vaccine in HIV-positive Women

University Hospital Virgen de las Nieves

NCT06485154 ACTIVE NOT RECRUITING

Post-Injectable Cabotegravir Antiretroviral Salvage Strategy Options Trial

University of Witwatersrand, South Africa

NCT06438146 RECRUITING

LIROH - Liraglutide for Obesity in HIV

Brigham and Women's Hospital

NCT04523519 RECRUITING

PrEP Intervention for People Who Inject Substances and Use Methamphetamine

San Francisco Department of Public Health

NCT06375304 NOT YET RECRUITING

The Antiretroviral Speed Access Program Switch (ASAP-Switch) Study

McGill University Health Centre/Research Institute of the McGill University Health Centre

NCT04553081 RECRUITING

2DR Versus 3DR in a Prospective Randomized Controlled Switch Trial

University Hospital, Ghent

NCT04616963 ACTIVE NOT RECRUITING

Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis

University of California, San Diego

NCT04875819 RECRUITING

Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV

Thomas Benfield

NCT03132311 RECRUITING

Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected Individuals

Oswaldo Cruz Foundation

NCT06104306 COMPLETED

Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)

Gilead Sciences

NCT05514509 COMPLETED

A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories

ViiV Healthcare

NCT06576024 COMPLETED

Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in HIV-infected People

LiuZhou People's Hospital

NCT04952766 COMPLETED

Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults

Centre Hospitalier Régional d'Orléans

NCT04782180 COMPLETED

PrEP at a Syringe Services Program

University of Miami

NCT05374525 COMPLETED

A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States

ViiV Healthcare

NCT04770701 COMPLETED

Protect and Improve Cluster of Differentiation 4 (CD4) Cells and B Cells Lymphocytes

Trieu, Nguyen Thi, M.D.

NCT03360682 COMPLETED

Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients

Fundacion Clinic per a la Recerca Biomédica

NCT07193875 COMPLETED

Efavirenz (EFV) Intensification

Washington University School of Medicine

NCT05528653 COMPLETED

Telehealth as a Modality to Increase the Uptake of PrEP Services in Black and Latino: "e-PrEP"

Vivent Health

NCT04233372 COMPLETED

Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study

Hospital Clinic of Barcelona

NCT04666792 COMPLETED

PrEParing Family Planning Clinics to Streamline Integration of HIV Prevention Services for Young Women in Kenya

University of Washington

NCT03825536 COMPLETED

Effect of Methamphetamine on Residual Latent HIV Disease Study

University of California, San Francisco

NCT04982614 COMPLETED

HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini

Columbia University

NCT03670316 COMPLETED

Effectiveness of a Smoking Cessation Algorithm Integrated Into HIV Primary Care

University of Alabama at Birmingham

NCT04530630 COMPLETED

Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant

Weill Medical College of Cornell University

NCT04880395 COMPLETED

Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3

Fundación Huésped

NCT05898841 COMPLETED

Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load

Fundacion SEIMC-GESIDA

NCT05549180 COMPLETED

Phase IV, a Clinical Trial to Assess Safety and Convenience of the Change From DTG/3TC to BIC/FTC/TAF in People With HIV, Good Virological Control and Neuropsychiatric Vulnerabilities

Fundacion SEIMC-GESIDA

NCT04884139 COMPLETED

DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV:

Fundacion SEIMC-GESIDA

NCT04665375 TERMINATED

Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF?

University Health Network, Toronto

NCT06185452 COMPLETED

Implementation of Out-of-HOspital Administration of the Long-Acting Cabotegravir+Rilpivirine

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

NCT03771638 COMPLETED

DOT Diary Mobile App for Pre-Exposure Prophylaxis Adherence in Young Men

Public Health Foundation Enterprises, Inc.

NCT04636437 COMPLETED

Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NCT04664998 COMPLETED

Alignment of PrEP Use With HIV Risk in Young Women and Men

University of Washington

NCT02732730 COMPLETED

Uptake and Adherence to Daily Oral PrEP as a Primary Prevention Strategy for Young African Women: A Vanguard Study

HIV Prevention Trials Network

NCT07014189 COMPLETED

Nevirapine / Lamivudine for HIV Maintenance Therapy

Cantonal Hospital of St. Gallen

NCT05030766 COMPLETED

Testing Integrative Smoking Cessation for HIV Patients

University of Miami

NCT05072093 COMPLETED

Parrying the Pitfalls of PrEP: Project PEACH

Emory University

NCT03226821 COMPLETED

Body Composition and Adipose Tissue in HIV

Columbia University

NCT04669678 COMPLETED

Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa

University of Alabama at Birmingham

NCT04982445 COMPLETED

Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.)

ViiV Healthcare

NCT04442737 COMPLETED

A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain

Janssen Scientific Affairs, LLC

NCT04487145 COMPLETED

Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy

University of California, San Francisco

NCT04079218 COMPLETED

Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial

Kerry Murphy

NCT05602506 COMPLETED

Safety, Tolerability, and Efficacy of a Dose Reduction Strategy Based on Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-infected Adults

Fundacion Clinic per a la Recerca Biomédica

NCT02938377 COMPLETED

Alcohol Research Consortium in HIV-Intervention Research Arm

University of Alabama at Birmingham

NCT05549726 COMPLETED

SEARCH CAB LA Dynamic Choice HIV Prevention Study Extension

University of California, San Francisco

NCT05284409 COMPLETED

Comparative Study Between the Prophylactic Intravenous Administrations of Acetaminophen vs Dexamethasone vs Pethidine Regarding the Incidence of Shivering Induced by Single Shot Spinal Anesthesia in the Orthopedic Surgeries of the Lower Limbs

Ain Shams University

NCT03675815 COMPLETED

Body Composition Sub-study of the D2EFT Trial

Kirby Institute

NCT04650269 COMPLETED

Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program

University of Miami

NCT02815566 COMPLETED

Bone Health in Aging HIV Infected Women

University Health Network, Toronto

NCT03986697 WITHDRAWN

How Does Antiretroviral Therapy Affect Coronary Atherosclerosis: a Serial CT Study

University of Liverpool

NCT04418037 COMPLETED

DHFS for Medication Adherence Support During Hospital Admissions for Person Living With HIV

University of California, San Diego

NCT05156658 WITHDRAWN

Pharmacokinetic Interactions of ENG Subdermal Implants with Long-Acting Cabotegravir (CAB-LA) and LA Rilpivirine (RPV-LA) (CARLA)

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NCT05289986 TERMINATED

The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients

Chelsea and Westminster NHS Foundation Trust

NCT02691065 COMPLETED

Protease Inhibitor Vs. Raltegravir-based ART and Inflammation in HIV Infection

McGill University Health Centre/Research Institute of the McGill University Health Centre

NCT04585737 COMPLETED

Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF

Charlotte-Paige Rolle, MD

NCT04076423 COMPLETED

A Phase IV Study to Assess the Impact of the Change of Antiretroviral Treatment From Dual Therapy to Triple Therapy on Inflammation in Patients With HIV Infection

Fundacion SEIMC-GESIDA

NCT04298697 COMPLETED

Biomarkers for Event-driven PrEP Adherence

Emory University

NCT04240210 TERMINATED

Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)

Midland Research Group, Inc.

NCT03502005 COMPLETED

Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1

Midland Research Group, Inc.

NCT04166474 COMPLETED

Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin

Helen Reynolds

NCT02844634 COMPLETED

Tenofovir/Emtricitabine With Doxycycline for Combination HIV and Syphilis Pre-exposure Prophylaxis in HIV-negative MSM

British Columbia Centre for Disease Control

NCT04050540 COMPLETED

Doxycycline PEP for Prevention of Sexually Transmitted Infections Among Kenyan Women Using HIV PrEP

University of Washington

NCT05405751 COMPLETED

Simplified Model of Linkage and Retention to Care, Using a Mobile Unit and a Same-day Test and Treat Approach Among Excluded Population. (SIMPLIFIED)

Fundacion SEIMC-GESIDA

NCT04431518 COMPLETED

Pharmacokinetics of JULUCA in Hemodialysis

Indiana University

NCT04904406 COMPLETED

Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals

Thomas Benfield

NCT04944654 TERMINATED

Efficacy, Tolerability and Acceptability of Biktarvy by TPLWH

Chelsea and Westminster NHS Foundation Trust

NCT02659761 TERMINATED

Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs

University College Dublin

NCT05243602 COMPLETED

BFTAF Elderly Switch Study

University of Nairobi

NCT02620150 COMPLETED

SSRI Effects on Depression and Immunity in HIV/AIDS

University of Pennsylvania

NCT02881762 COMPLETED

Maraviroc Efficacy for Hepatitis C

University of Maryland, Baltimore

NCT04388904 COMPLETED

Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)

The Crofoot Research Center, Inc.

NCT05159531 TERMINATED

Virtual PrEP: Rendering PrEP Delivery More Efficient

Unity Health Toronto

NCT03999411 COMPLETED

Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients

University of Miami

NCT04754698 COMPLETED

COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS

University of Sao Paulo General Hospital

NCT04538040 COMPLETED

Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine

Quest Clinical Research

NCT04549467 COMPLETED

Efficacy of Dolutegravir Plus Lamivudine in HIV-1-infected Treatment-naïve Adults Without a Baseline Genotyping Test

Fundacion IDEAA

NCT06177574 COMPLETED

Study of Bictegravir/Emtricitavine/Tenofovir Alafenamide in HIV-1 Infected naïve Patients Using Test and Treat Stategy Rapid-initiation Model of Care: BIC-NOW Clinical Trial (BIC-NOW)

Carmen Hidalgo Tenorio

NCT03826199 COMPLETED

Evaluation of Pre-exposure Prophylaxis Cascade in Pregnant and Breastfeeding Women in Cape Town (Formative Study)

University of California, Los Angeles

NCT04249037 TERMINATED

Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIV

University of Colorado, Denver

NCT03797014 COMPLETED

B/F/TAF Switch Study for HIV-HBV Coinfection

University of Maryland, Baltimore

NCT03194308 COMPLETED

Safer Conception for Women - Understanding Use of Periconception PrEP

Massachusetts General Hospital

NCT02210715 COMPLETED

Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients

McGill University Health Centre/Research Institute of the McGill University Health Centre

NCT03302299 COMPLETED

Alcohol Drinkers' Exposure to Preventive Therapy for TB (ADEPTT)

University of California, San Francisco

NCT03998176 COMPLETED

Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE

University of Nebraska

NCT03626467 COMPLETED

A Clinical Trial to Evaluate the Immunogenicity of the Nonavalent Vaccine Against Human Papillomavirus in Men Infected by HIV Who Have Sex With Men. GESIDA 10017

Fundacion SEIMC-GESIDA

NCT04340388 COMPLETED

Contribution of Dolutegravir to Obesity and Cardiovascular Disease

Augusta University

NCT04135937 COMPLETED

Mobile Evidence-Based Smoking Cessation for Veterans Living With HIV (MESH)

VA Office of Research and Development

NCT03823911 COMPLETED

Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication

University of Maryland, Baltimore

NCT03290391 COMPLETED

Linking Infectious and Narcology Care-Part II

Boston Medical Center

NCT05718011 COMPLETED

Prevention of Shivering After Spinal Anesthesia

Pakistan Air Force (PAF) Hospital Islamabad

NCT03855176 COMPLETED

Effectiveness of Booster With 1 or 2 Doses of HAV Vaccine Among HIV-infected Patients

National Taiwan University Hospital

NCT04040075 TERMINATED

Testing the Safety and Efficacy of Commercial Drug Biktarvy in Subjects Known to Have the 184 Resistance Mutation to a Component in Biktarvy

Southampton Healthcare, Inc.

NCT02924389 TERMINATED

Dolutegravir in Reservoirs

Emory University

NCT03842436 COMPLETED

Feasibility and Acceptability of Digital Pills to Monitor PrEP Adherence in MSM With Substance Use

Brigham and Women's Hospital

NCT03532425 TERMINATED

B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults

University of Alberta

NCT05606055 COMPLETED

The Benefits of Immediate Treatment Initiation Without Immunovirological Data Compared to Conventional BIC / FTC / TAF Treatment in Naive Patients With Type 1 HIV (Human Immunodeficiency Virus) Infection

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

NCT03348163 TERMINATED

(mo)BETTA Trial in Transwomen for Optimization of ART

The University of Texas Health Science Center, Houston

NCT02712801 COMPLETED

Antiretroviral Regime for Viral Eradication in Newborns

National Center for Women and Children's Health, China CDC

NCT02743598 TERMINATED

Liraglutide for HIV-associated Neurocognitive Disorder

Temple University

NCT03088410 COMPLETED

Study of HIV-Infected and Uninfected Pregnant Woman/Child Dyads in Gaborone, Botswana

Ann & Robert H Lurie Children's Hospital of Chicago

NCT03070600 COMPLETED

PrEP Implementation for Mothers in Antenatal Care

University of Washington

NCT03685500 COMPLETED

A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c)

Fundacion SEIMC-GESIDA

NCT01936857 COMPLETED

Buprenorphine to Improve HIV Care Engagement and Outcomes

Oregon Health and Science University

NCT02519777 COMPLETED

Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05295394 WITHDRAWN

Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot Study

Pedro Cahn

NCT03499483 COMPLETED

Biktarvy for Non-Occupational Post-Exposure Prophylaxis (nPEP)

Fenway Community Health

NCT03683524 COMPLETED

EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MUTATIONS

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

NCT02938013 COMPLETED

deLIVER: Direct Acting Antiviral Effects on the Liver

Johns Hopkins University

NCT04039217 COMPLETED

Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM

Emory University

NCT03512210 COMPLETED

Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NCT04229290 COMPLETED

Second-line Switch to Dolutegravir Study

University of Nairobi

NCT04094870 COMPLETED

A Pilot Trial of Perinatal Depression Treatment in HIV Infected Women

University of North Carolina, Chapel Hill

NCT05110469 COMPLETED

Comparison of MgSO4 Versus Meperidine for Prevention of Shivering During Spinal Anesthesia

AnestesiaR

NCT03387462 COMPLETED

DOT Diary Optimization Pilot: A Pilot Study to Optimize the DOT Diary App to Measure PrEP Adherence

Public Health Foundation Enterprises, Inc.

NCT04192487 COMPLETED

Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea

Napo Pharmaceuticals, Inc.

NCT03052010 COMPLETED

The Partners Scale-Up Project

University of Washington

NCT03350672 COMPLETED

Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir Alafenamide

Philadelphia Fight

NCT04551573 WITHDRAWN

A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects

Yale University

NCT04191278 WITHDRAWN

Mobile Health Interventions for Medication Adherence Among PLWH

Duke University

NCT03374358 COMPLETED

Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir

Helsinki University Central Hospital

NCT03447873 COMPLETED

Tripe Versus Dual Antiretroviral Therapy in HIV-infected Patients With Virological Suppression (Tridual)

Hospitales Universitarios Virgen del Rocío

NCT01818258 COMPLETED

IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children

International Maternal Pediatric Adolescent AIDS Clinical Trials Group

NCT04965662 COMPLETED

The Role of Home Packs of HIV PEPSE in High Risk Individuals

Guy's and St Thomas' NHS Foundation Trust

NCT02584140 COMPLETED

Pre-exposure Prophylaxis (PrEP) Adherence Enhancement Guided by iTAB and Drug Levels for Women

University of California, Los Angeles

NCT03813979 WITHDRAWN

Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compared to Matched Controls.

Radboud University Medical Center

NCT04050371 COMPLETED

Study of Truvada for HIV Pre Exposure Prophylaxis Using Daily Directly Observed Therapy to Look at Potential Interactions Between Truvada and Hormone Therapy

University of California, San Francisco

NCT03630549 COMPLETED

Village-based vs Clinic-based ART Care - a Cluster Randomized Controlled Trial in Lesotho

Niklaus Labhardt

NCT03205566 COMPLETED

Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection

Guy's and St Thomas' NHS Foundation Trust

NCT03126370 COMPLETED

Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF)

University of Colorado, Denver

NCT02533934 COMPLETED

Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant

University of California, San Francisco

NCT03675555 COMPLETED

Prophylactic Mirtazapine or Dexamethasone for Post-spinal Anesthesia Shivering

Ain Shams University

NCT02357368 COMPLETED

Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk

Lisa Haddad

NCT04183738 WITHDRAWN

Inflammation and Co-Infections in D²EFT

Kirby Institute

NCT03163277 TERMINATED

Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X)

Giovanni Di Perri

NCT02577042 COMPLETED

Study of the Effect of Atorvastatin for Reducing Aging-related Complication in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

NCT03723525 COMPLETED

Package of Care to Improve Retention in ART and Mortality Among Treatment Naive HIV Infected Individuals

National Centre for AIDs and STD Control, Nepal

NCT02354053 COMPLETED

Evaluation of Switching From Current cART to Triumeq With Adherence Support Will Enhance HIV Control in Vulnerable Populations

McGill University Health Centre/Research Institute of the McGill University Health Centre

NCT03693508 COMPLETED

A Clinical Trial to Evaluate the Efficacy and Safety of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide as a First-line Treatment in Naïve Patients With HIV-1 Infection With Severe Immunosuppression

Fundacion SEIMC-GESIDA

NCT04249804 COMPLETED

the Use of Magnesium Sulfate for Prevention of Postspinal Shivering

Cairo University

NCT02431975 COMPLETED

Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial

Columbia University

NCT02840513 TERMINATED

Smartphone App and CO Self-monitoring for Smoking Cessation

Alain Nordmann

NCT02905890 COMPLETED

The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis

London School of Hygiene and Tropical Medicine

NCT02935075 COMPLETED

Optimization of Antiretroviral Therapy

Shanghai Public Health Clinical Center

NCT02945163 COMPLETED

Dosing of Tenofovir and Efavirenz in Antiretroviral Therapy

Shanghai Public Health Clinical Center

NCT03067285 COMPLETED

A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study

Fundacion SEIMC-GESIDA

NCT02401828 COMPLETED

The Dolutegravir Antiretroviral Mono-Therapy for HIV Trial

Erasmus Medical Center

NCT02990312 WITHDRAWN

Impact of Sirolimus and Maraviroc on CCR5 Expression and the HIV-1 Reservoir in HIV-infected Kidney Transplant Recipients

University of Maryland, Baltimore

NCT03218592 COMPLETED

ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-Adherence

University of North Carolina, Chapel Hill

NCT02429869 COMPLETED

Impact of Everolimus on HIV Persistence Post Kidney or Liver Transplant

University of California, San Francisco

NCT03642704 COMPLETED

HIV Diagnosis and Treatment at Birth for Newborn With High Risk HIV Exposure

ANRS, Emerging Infectious Diseases

NCT03667547 COMPLETED

Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851)

Merck Sharp & Dohme LLC

NCT03087890 COMPLETED

Impact of Cotrimoxazole Use in Immunocompetent HIV Patients on Carriage of Antimicrobial Resistant Bacteria

University of Bergen

NCT03101644 COMPLETED

Optimization of Darunavir Therapy and Dosage Recommendations

Université Catholique de Louvain

NCT03160105 COMPLETED

Evaluation of a Simplified Strategy for the Long-term Management of HIV Infection (Simpl'HIV)

Calmy Alexandra

NCT03221582 TERMINATED

Impact of Hepatitis C Therapy and Bone Health

Dallas VA Medical Center

NCT03033836 COMPLETED

Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine in HIV-1 Infected Transgender Women

Fundación Huésped

NCT02531321 TERMINATED

Protease Inhibitors and Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics

University of Southern California

NCT02667678 COMPLETED

5 Years Follow-up Evaluation of Deterioration Kidney Biomarkers of HIV Patients

Centre Hospitalier Universitaire de Saint Etienne

NCT03838497 COMPLETED

Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Among HIV-infected Adults

Korea University Guro Hospital

NCT03314064 COMPLETED

Phase 4 Study of Dolutegravir (DTG) in Russian Federation

ViiV Healthcare

NCT02316444 COMPLETED

Strategies for the Prevention of Hepatitis B Among HIV Infected Patients in Uganda

Fred Hutchinson Cancer Center

NCT02383355 COMPLETED

Effects of Raltegravir Based Regimen on Platelet Reactivity, Platelet-monocyte Aggregation and Immune Activation

Radboud University Medical Center

NCT02445989 COMPLETED

Effects of Contraceptive Ring on Vaginal Microbiota, HIV Shedding and Local Immunity

University of Washington

NCT03757117 COMPLETED

Gender-Affirmative Transgender Care to Improve the HIV Treatment Cascade

Asociación Civil Impacta Salud y Educación, Peru

NCT02771054 COMPLETED

Tenofovir Alafenamide Fumarate (TAF) Effect on Residual Intrathecal Immune Activation

Göteborg University

NCT03679052 COMPLETED

Prophylactic Mirtazapine or Clonidine for Post-spinal Anesthesia Shivering

Ain Shams University

NCT03679065 COMPLETED

Prophylactic Paracetamol or Dexamethasone for Post-spinal Anesthesia Shivering

Ain Shams University

NCT02339038 COMPLETED

Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia

National Institutes of Health Clinical Center (CC)

NCT02770508 COMPLETED

Darunavir/Ritonavir + Lamivudine Versus Darunavir/Ritonavir +Emtricitabine/Tenofovir in Naïve HIV-1 Infected Subjects

Fundación Huésped

NCT02042001 COMPLETED

Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects

Azienda Ospedaliera San Gerardo di Monza

NCT03302351 COMPLETED

Dexmedetomidine, Ketamine and Dexmetedomidine-Ketamine Combination for Control of Shivering During Regional Anaethesia

Assiut University

NCT02167386 COMPLETED

PrEPared and Strong: Clinic-Based PrEP for Black MSM

Columbia University

NCT02509195 COMPLETED

SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over

St Stephens Aids Trust

NCT02401230 COMPLETED

PrEP, Lube, and the Rectal Mucosa in MSM at Risk of HIV

Emory University

NCT03402815 COMPLETED

Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients.

University Of Perugia

NCT03250910 COMPLETED

Generic VEL/SOF With or Without RBV for HIV/HCV Coinfected Patients

National Taiwan University Hospital

NCT02500446 COMPLETED

Dolutegravir Impact on Residual Replication

University of Melbourne

NCT02308332 COMPLETED

Effect of SwitChing AtriPla to Eviplera on Neurocognitive and Emotional Functioning

UMC Utrecht

NCT02529059 COMPLETED

SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms

St Stephens Aids Trust

NCT02477527 COMPLETED

Atripla to Stribild Switch Study to Evaluate Sleep Disturbances

Midtown Medical Center, Tampa, FL

NCT02351908 COMPLETED

Renal Integrase Study

St Stephens Aids Trust

NCT02513147 COMPLETED

HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen

Hospital Universitari Vall d'Hebron Research Institute

NCT02547844 COMPLETED

Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla

Hospital Universitari Vall d'Hebron Research Institute

NCT02634073 COMPLETED

A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers

ViiV Healthcare

NCT02447016 TERMINATED

Decrease of Neuropsychiatric Side Effects After Switching From Atripla to Eviplera

Sheba Medical Center

NCT02198443 COMPLETED

Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open.

Fundacion Clinic per a la Recerca Biomédica

NCT02632474 COMPLETED

ART Drug Dosage Adjustment in HIV-infected Population

Shanghai Public Health Clinical Center

NCT02878564 COMPLETED

Effect of Schistosomiasis Mansoni on HIV Susceptibility and Female Genital Immunology

University of Toronto

NCT01663558 WITHDRAWN

Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV

United States Naval Medical Center, San Diego

NCT02487706 COMPLETED

Assessment of Dolutegravir Removed by Hemodialysis in HIV-infected Patients With End-stage Renal Disease

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

Data: ClinicalTrials.gov